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Preface: 
 
I am a graduate student in the Master of Public Health Program at Simon Fraser 
University.  The Fraser Health Supervised Consumption Site Evaluation Plan will serve as my 
Capstone Project in completion of my MPH degree.  From May-July 2016, I had the opportunity 
to complete my practicum with the Fraser Health Authority’s Population and Public Health 
Department.  I was fortunate to be asked to return to Fraser Health to complete my Capstone and 
assist with the evaluation plan for their supervised consumption sites.   
The recent number of overdose deaths resulting from illicit drug use is a tragedy that has 
shaken our entire province.  I am grateful to have had the opportunity to work alongside a team 
attempting to address this crisis and prevent future tragedies.  I hope that this evaluation plan will 
help to reduce further loss in our communities.   
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Executive Summary: 
 
In 2016, British Columbia experienced a devastating number of illicit drug overdose 
deaths resulting in the declaration of a public health emergency. In light of this crisis, the Fraser 
Health Authority launched their Enhanced Overdose Response Strategy which included 
submitting applications to Health Canada for the operation of two supervised consumption sites 
in Surrey, British Columbia.  While sometimes controversial, there is abundant research 
evidence in the literature supporting the effectiveness of supervised consumption sites in 
reducing overdose deaths and infectious disease risk behaviour, increasing referrals and entry to 
detoxification and addiction treatment programs, improving access for people who use drugs to 
medical treatment, fostering safer injection practices, decreasing drug-related public disorder and 
producing cost savings.  Nevertheless, it is still paramount to critically evaluate both supervised 
consumption sites to understand the health and community impacts they are having in the Surrey 
community.   
The purpose of this evaluation is to assess the impact and effectiveness of the supervised 
consumption sites being implemented by Fraser Health.  A first step in any evaluation is to 
develop a comprehensive evaluation plan.  The evaluation plan for Fraser Health Supervised 
Consumption Sites that follows has been created in consultation with several key stakeholders  
(Fraser Health, community partners, the City of Surrey, and the Royal Canadian Mounted Police) 
to ensure that the plan meets their objectives and needs.  The evaluation will focus on three main 
questions:  
1. Are the services being provided as intended at the two supervised consumption sites? 
2. Are SCS services adapting to client and community needs? 
3. Are the intended benefits of each supervised consumption site being recognized? 
  11 
Each main evaluation question is accompanied by several sub-questions that will be assessed 
using specific indicators.  Both the indicators and data collection strategies have been adapted 
from the methodology used in previous evaluations of existing supervised consumption facilities.  
Comparing the results from the current evaluation with previous evaluation findings allows for 
greater validity and reliability despite limited time and resources.   
This evaluation is designed to be utilization-focused to ensure Fraser Health and other key 
stakeholders are able to use the findings to inform decision-making for the sites.  Therefore, an 
evaluation matrix including indicators, data sources, data collection strategies, responsibilities, 
and timeframes will serve as a working document for the Fraser Health evaluation team and can 
be adapted as the evaluation progresses. A mixed methods approach will be used for data 
collection and analysis.  Data collection will require cooperation among several groups of 
stakeholders and will be collected through an access database, surveys, key informant interviews, 
tracking tools, comment cards, and secondary data sources such as the City of Surrey and 
RCMP. Data analysis will be focused on addressing the evaluation questions, and the findings 
will be summarized in a detailed report to be shared with stakeholders.  Finally, the findings will 
be disseminated through news releases, press conferences, community and stakeholder 
consultations, and on the Fraser Health website to ensure all stakeholders and the general public 
are aware of the impact of the supervised consumption sites. 
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1. Introduction to the Evaluation Plan 
 
 Surrey has experienced a dramatic increase in both fatal and non-fatal opioid-related 
overdoses, as has British Columbia (BC) as a whole.  The overdose crisis in Surrey is complex 
and stems from decades of ineffective policies, increased impact of the broader social 
determinants of health (i.e. physician prescribing practices, homelessness, poverty), and the 
emergence of potent opioids such as fentanyl.  Fraser Health (FH) recognizes that ideally all FH 
residents are free of substance use, are securely employed, are supported by families, and are 
stably housed.  However, large numbers of individuals who are opioid dependent reside within 
FH, and with rates of relapse from abstinence treatment programs being as high as 60%, 
expecting people who use drugs (PWUD) to achieve abstinence is unrealistic even with the 
strongest community services and supports (van den Brink & Haasen, 2006).  Therefore, FH has 
adopted a strategy with actions aimed at meeting the needs of PWUD regardless of which stage 
they are at along the prevention to recovery continuum.   
 As part of their strategy, FH has chosen to implement evidence based harm reduction 
interventions to help mitigate drug related harms in the Surrey community including Opioid 
Agonist Treatment (OAT) programs, enhanced naloxone distribution and training, increased 
distribution of sterile consumption equipment and needle collection, and supervised consumption 
services.  The most controversial of these strategies is the implementation of two supervised 
consumption sites (SCS) in the city of Surrey, BC.  Although evidence from SCS facilities in 
Vancouver, Australia, and Europe have demonstrated that SCS are effective at reducing drug 
related harms and improving public order, supervised consumption services continue to face 
tremendous opposition (Tyndall et al., 2007; Wood et al., 2004a).  In addition, SCS in Canada 
are required to meet extensive criteria to receive an exemption under the Controlled Drugs and 
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Substances Act, before they can be implemented (Smith, 2015).  In order to receive an 
exemption, FH is required to have the support of key stakeholders in the community and develop 
measures to address key stakeholder concerns.  To address the concerns of relevant stakeholders, 
FH has committed to conducting a comprehensive evaluation that will include outcomes and 
metrics related to services provided (including outreach), health outcomes, and community 
impact.  The plan for this evaluation is detailed in the report that follows and will provide the 
basis for all evaluation related activities for both FH SCS sites.    
 
1.1  Purpose of the Evaluation 
The purpose of this evaluation is to assess the impact and effectiveness of the SCS being 
implemented by FH in the city of Surrey. Evaluating the SCS is important for several reasons:  
" First, the evaluation findings will provide evidence that will be important for SCS 
stakeholders.  In SCS applications to Health Canada and in community consultations, FH 
committed to conducting an evaluation of each site.  To ensure that FH is remaining 
accountable to stakeholders and the community about the impact of the SCS, obtaining 
objective measures of performance and disseminating the findings is crucial.  
" Second, an evaluation will help determine if the SCS is offering the appropriate services 
and meeting client and community needs.  
" Third, the evaluation will determine whether or not the intended benefits of the SCS are 
being achieved and will provide further evidence on the impact of supervised 
consumption services. 
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1.2   Intended use of the Evaluation 
The results of this evaluation will be used to demonstrate the impact of SCS on outcomes of 
interest to various stakeholders.  The evaluation will also be used to inform several process 
indicators that could lead to refinement or modification of site operation and policies.  Finally, 
the evaluation will add to the existing evidence base regarding the effectiveness of SCS.   
 
1.2.1  Primary Intended Users of the Evaluation   
The primary intended users of this evaluation are FH Senior Executive Committee, the 
SCS implementation team (including representatives from FH Population and Public Health 
(PPH) and Mental Health and Substance Use (MHSU) departments), SCS staff, City of Surrey, 
Royal Canadian Mounted Police (RCMP), and the Surrey Business Improvement Association 
(BIA).  The evaluation questions identified in this report have been established based on the 
interests of the primary intended users.   
 
1.2.2  Secondary Intended Users of the Evaluation 
The secondary intended users of this evaluation are the SCS clients, PWUD in the 
community, residents in the community, the Surrey School District, Ministry of Health, Health 
Canada, the BC Centre for Disease Control (BCCDC), Lookout Emergency Aid Society and 
other community partners.  While the evaluation questions identified in this report may be of 
interest or have an impact on these groups, these stakeholders were not involved in structuring 
the evaluation.  Therefore, these groups have been identified as secondary intended users.   
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1.3   Scope and Limitations 
This evaluation is focused on examining only those evaluation questions most critical to the 
successful operation and intended outcomes of the sites.  The evaluation has a narrowed focus 
because it is bounded by limited resources and time.  Also, because sufficient evidence exists in 
the literature demonstrating the effectiveness and impact of SCS, and because new findings are 
unlikely to emerge at the FH sites, duplication of rigorous research studies from other facilities is 
unnecessary.  Therefore, this evaluation will focus more on ensuring the interests and 
expectations of intended users are satisfied as opposed to adding to the abundant literature 
examining SCS.   
Because the SCS primary goals do not involve adding to the scientific literature, the SCS 
will not be based upon a cohort of injection drug users such as the Scientific Evaluation of 
Supervised Injecting (SEOSI) cohort at Vancouver’s supervised injection facility (SIF)1, Insite.  
While Insite operated under an exemption from the Controlled Drug and Substances Act, its 
operation was contingent upon the construction of a rigorous evaluation, and the FH SCS will 
not face the same requirements (Boyd, 2013). The absence of a study cohort may affect the 
validity and reliability of the evaluation findings; nevertheless, the current evaluation has tried to 
replicate the methodology from evaluations of existing SCS wherever possible.  As a result, most 
of the findings from the current evaluation will have the ability to be compared to existing 
evaluation research to ensure validity and reliability.  Also, the evaluation will rely on secondary 
data from several sources to minimize resources in data collection and for triangulation of data.  
                                               
1 The terms supervised injection facilities (SIFs) and supervised consumption sites (SCS) are often used interchangeably.  For the 
purposes of this report, SCS has been used to describe the FH sites.  The BC Ministry of Health has requested that new 
consumption facilities be called “supervised consumption sites” to allow for alternative modes of administration (i.e. oral & 
intranasal administration).  Existing SIFs such as Insite in Vancouver are limited to injection drug use and do not accommodate 
other routes of administration, while SCS will allow consumption of drugs orally or intranasally.  By allowing drug users who 
consume drugs orally or intranasally to access the sites, SCS may be more accessible to the drug user population.   
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2. Program Profile 
 
2.1 Organizational Context 
The Fraser Health Authority is one of five regional health authorities in BC delivering 
prevention, hospital, residential, community-based and primary health care services.  FH is the 
fastest growing health authority in B.C. serving over 1.8 million people.  The region serviced by 
FH runs west to east from Burnaby to Hope and north to south from Boston Bar to the 
Canada/U.S. border.  This geographic area, referred to as the Fraser Region, includes 16 
municipalities across three health services delivery areas: Fraser North, Fraser East, and Fraser 
South. The Fraser Region is home to one of the most economically, culturally, and 
geographically diverse populations in B.C. including 40% of the province’s immigrants and 
38,100 First Nations people.     
Fraser Health’s mission is “to improve the health of the population and the quality of life 
of the people [they] serve.”  As a result, FH delivers a full continuum of health services, from 
broad population health programs to hospital-based services.  These services are mainly 
delivered by FH physicians and staff in facilities throughout the Fraser Region; however, some 
FH services are contracted out and delivered through other providers.  The department involved 
in FH’s Overdose Prevention and Response Strategy including the implementation and operation 
of SCS are PPH and MHSU.  Both programs work closely with internal and external 
stakeholders to provide public health and substance use programs and services to communities 
throughout the Fraser Region and are coordinating their efforts on the implementation of the SCS 
sites. 
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2.2  Program Background  
To understand why FH is implementing two SCS facilities, it is important to discuss the 
harms that are associated with illicit drug consumption and the various approaches that have 
been used to minimize these harms. 
 
2.2.1  Harms associated with illicit drug consumption  
 Illicit drug use is prevalent in Canada with 10.2% of people reporting using cannabis and 
1.7% of people reporting using cocaine or crack, speed, ecstasy, hallucinogens (excluding salvia) 
and heroin (CADUMS, 2012; Health Canada, 2011).  As well, abuse of psychoactive 
pharmaceutical drugs including opioid pain relievers, (such as Percodan, Demerol and 
OxyContin); stimulants, (such as Ritalin, Concerta, Adderall and Dexedrine); and tranquillizers 
and sedatives, (such as Valium, Ativan and Xanax) are reported by 0.7% of Canadians (Health 
Canada, 2011).  Significant health consequences are associated with illicit drug use including 
non-fatal and fatal overdose, blood-borne viruses, and cutaneous infections.  
 Overdoses are a leading cause of morbidity and mortality among illicit drug users.   The 
reported prevalence of non-fatal overdoses among PWUD ranges between 20% and 70% per 
lifetime depending on the region in Canada (Kerr et al., 2007a; Kinner et al., 2012; Silva et al., 
2013).  Although only a few provinces actively report drug related overdose deaths, coroners’ 
reports from several Canadian provinces indicate that hundreds of overdose deaths occur each 
year (Canadian Drug Policy Coalition, 2012).  Recently, the emergence of fentanyl has caused an 
alarming spike in overdose deaths (Socias & Ahamad, 2016).  Coroners’ reports from Canada’s 
largest provinces indicate that the number of overdose deaths across Canada in 2016 could be in 
the thousands (Woo, 2016).  For example, in 2016, 922 illicit drug related overdose deaths 
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occurred in BC alone –a 60% increase from 2015 (Coroner’s Service Report, 2017; Russel, 
2016).  In the past few years, fentanyl has been detected in various street drugs across Canada 
and is popular among opioid users and drug dealers because of its potency (Jafari, Buxton, & 
Joe, 2015).  Because the difference between an effective and fatal dose of fentanyl is very small, 
and because it is an unregulated substance in Canada with variable doses of the drug appearing in 
pill or powder form, fentanyl use is associated with a high risk of overdose death (Young, 2015).  
Also, fentanyl is often sold as fake OxyContin or heroin resulting in many drug users 
unknowingly exposing themselves to a more powerful opioid than expected (Young, 2015).     
 In addition to the risk of overdose, injection drug use is associated with several serious 
drug-related harms including transmission of blood-borne infections and injection site bacterial 
infections (Hunt, Trace, & Bewley-Taylor, 2005).  Human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV) are the most common blood-borne infections contracted by people who 
inject drugs (PWID) worldwide.  In Canada, an estimated 15-20% of PWID have HIV, and 
PWID account for 12.8 % of reported HIV cases (Public Health Agency of Canada, 2010).  
Some estimates indicate PWID are approximately 59 times more likely to contract HIV than 
people who do not inject drugs (Degenhardt & Hall, 2012; Challacombe, 2017).  Although 
advances in antiretroviral therapy have improved the survival and quality of life of HIV infected 
persons, HIV is still responsible for a significant number of deaths among PWID each year in 
Canada (Canadian HIV/AIDS Legal Network, 2005).  HCV is even more prevalent among 
PWID in Canada, with an estimated 68% of injection drug users having or having had HCV in 
their lifetime (Challacombe, 2017).  In addition to the life years lost from these diseases, 
HIV/AIDS and HCV cost the Canadian health care system millions of dollars (Bayoumi & Zaric, 
2008). Finally, studies have shown that injection-related site bacterial and soft tissue infections 
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account for the majority of emergency room visits and hospitalizations among PWID in Canada 
(Kerr, 2004).  Cutaneous infections such as cellulitis and abscesses are common infections 
among PWID and mainly result from unhygienic injection practices (Lloyd-Smith, 2005).  
Clearly, the health consequences associated with illicit drug use severely impact many PWUD 
and result in death, disease, and tremendous costs to the health care system.  
 
2.2.2  Risk Factors associated with illicit drug consumption 
 PWUD are a high-risk group for overdose and infection as a result of various social 
determinants and individual characteristics. While most interventions focus on minimizing 
individual risk behaviours (such as educational interventions), it is important to recognize the 
limitations of these approaches.   Risk behaviours associated with illicit drug use are often 
shaped by a constellation of forces beyond the control of individual drug users, resulting from 
interactions between broader social and structural environments (Rhodes, 1997).  For instance, 
drug entrenched populations are often characterized by poor health, gender inequities, poverty, 
insufficient access to health care services, and a lack of housing and social supports that 
exacerbate health risks among PWUD (Fischer et al., 2004).  Indeed, lack of stable housing and 
poverty results in many PWUD consuming substances in public settings where exposure to 
police and other drug users can increase the risks associated with drug use (Small et al., 2007).    
 Rhode’s (2002) “risk environment” framework has improved the understanding of how 
various social and environmental factors influence the risk of individuals experiencing drug 
related harm, as well as the impact of interventions that aim to minimize these harms.  This 
research on the social context and physical environment of injection drug use suggests that drug 
consumption settings either facilitate safer consumption practices or limit such practices by 
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shaping individual ability to enact risk reduction measures (Rhodes, 2002).  Specifically, the risk 
of drug related harm in settings is often determined by the availability of sterile syringes and the 
ability to practice safe consumption techniques without disruption (Singer et al., 2000; Rhodes et 
al., 2006).  Research from the downtown eastside (DTES) of Vancouver indicates that injection 
drug users will partake in risky injection behaviour to protect themselves (and their drugs) from 
disruptions such as arrests or assaults in unregulated settings (Kerr, Small, & Wood, 2005a).  As 
a result, SCS act as an important intervention to minimize disruption to promote safe 
consumption practices, decrease the likelihood of police or public interference, and reduce the 
need for rushed drug consumption (Rhodes et al., 2006).  Also, the supervision provided by 
health professionals at the sites further mitigates the risk of unsafe injection practices and 
overdose deaths.  SCS have the common goal of improving access to sterile drug consumption 
equipment, hygienic consumption environments, sterile water, and adequate lighting.  These 
consumption services are often complemented by individual-focused educational and 
behavioural health interventions to help encourage safer consumption practices and encourage 
entry into addiction treatment programs (Rhodes et al., 2005). 
 Indeed, evidence from safer injection sites such as Insite indicates that frequent SIF users 
are less likely to rush and share syringes than less frequent SIF users (Stoltz et al., 2007).  
Moreover, consistent Insite users are more likely to use sterile water, swab injection sites, safely 
dispose of syringes, and cook or filter their drugs.   Therefore, SCS can help minimize major risk 
factors associated with HIV and HCV such as blood-to-blood contact that occurs when sharing 
contaminated syringes or other contaminated drug-use paraphernalia (Hunt et al., 2005).  As 
needle sharing is prevalent among drug users in Canada (Fischer et al., 1999; Wood et al., 2001), 
additional community interventions such as needle-exchange programs or distribution of safe 
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consumption equipment can also help reduce the risk of infection (Canadian HIV/AIDS Legal 
Network, 2005).   
 By reducing high-risk injection behaviours such as injecting alone, needle sharing, and 
rushed injecting, SCS also reduce the risk of fatal overdoses.  Clearly, shifting the injection 
setting to an SCS where health professionals monitor PWUD results in more immediate, life-
saving intervention (using oxygen or naloxone) in the event of an opioid overdose.  However, 
many individual risk factors still place PWUD at a high risk of overdose even if they have access 
to an SCS.  Individual characteristics such as drug use frequency, duration, main drug consumed, 
poly-drug use, and concurrent alcohol use can all influence a person’s risk of overdose (Fischer 
et al., 2004).  Also, people who use illicit substances with greater unpredictability in drug purity 
or formulations are more likely to experience overdose (Canadian HIV/AIDS Legal Network, 
2005).  For instance, the high potency of fentanyl and the frequency with which it is used to 
adulterate or cut other drugs results in tremendous overdose risk.  Finally, research has shown 
that non-fatal overdose events are independently associated with subsequent fatal overdoses 
(Caudarella et al., 2015).  These findings suggest that those individuals who engage in high-risk 
drug behaviours or who have experienced a non-fatal overdose should be targeted for overdose 
prevention interventions such as substitution therapies, drug treatment programs, and educational 
interventions.   
 
2.2.3  Harm Reduction in Canada  
 Harm reduction oriented programs are becoming more common in Canada to address 
health harms stemming from injection drug use.  Harm reduction as a social policy is relatively 
new in Canada, but is gaining more traction as opposed to the abstentionist or “zero tolerance” 
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policies towards drug use that have traditionally been used (Inciardi & Harrison, 2000).  The 
goal of a harm reduction approach is to reduce the adverse consequences of drug use among 
PWUD without requiring abstinence from drug use (Single, 1995).  Therefore, harm reduction 
strategies attempt to reduce the potential for drug related health harms and the likelihood that 
PWUD will overdose, contract HIV, HCV or experience other adverse health issues.  Ultimately, 
these strategies provide support and resources for PWUD that can help address extra-individual 
factors driving drug-related harm including housing, poverty, and access to health and social 
services (Inciardi & Harrison, 2000).    
 Canada has increasingly adopted harm reduction strategies to address substance use 
recognizing the limitations and unintended consequences stemming from drug prohibition and 
the criminalization of drug use. These harm reduction strategies are evidence-based and include 
addiction treatment (not requiring abstinence), needle-exchange programs or provision of sterile 
injection equipment, safe injection education, overdose prevention education and response 
training, and supervised consumption services (Canadian HIV/AIDS Legal Network, 2005).  
Among harm reduction strategies adopted in Canada, the most controversial and widely debated 
are SCS.   
 Although SCS have been successfully implemented across Europe, Australia, and North 
America, opposition in Canada has been strong with claims that such sites encourage drug use, 
nuisance, and disorder (Boyd, 2013).  Nevertheless, studies evaluating SCS refute these claims 
documenting decreased public injecting behaviour and drug-related public disorder (Kerr et al., 
2006).  Moreover, SCS have proven to be one of the most effective harm reduction strategies in 
reducing drug related harm and improving social integration among PWUD (Canadian 
HIV/AIDS Legal Network, 2005).  
  23 
2.2.4  History of Supervised Consumption Services  
 The first SCS emerged in Europe with a facility opening in the Netherlands in the early 
1970s (Dolan et al., 2000).  Similar sites in Switzerland and Germany followed throughout the 
1980s and 90s and by 2009, there were ninety-two SCS operating in sixty-one European cities 
(Hedrich et al., 2010).  In 2001, a site opened in Sydney, Australia called the Medically 
Supervised Injecting Centre (MSIC) after the King’s Cross area had experienced a 
disproportionate number of drug overdoses (Uniting, n.d.).  Finally in 2003, Insite opened in the 
DTES of Vancouver1 and became the first SIF in North America.   Insite was created in response 
to a spike in HIV infections and deaths from illicit drug use in the DTES of Vancouver in the 
1990s (Kerr, Oleson, Tyndall, Montaner, & Wood, 2005b).   
 Both MSIC and Insite were highly controversial pilot studies that were granted legal 
exemptions by their respective governments.  However, these exemptions were contingent on the 
generation of scientific evidence pertaining to the operation and impact of the facilities (Boyd, 
2013).  Therefore, both SIFs were required to conduct rigorous evaluations in order to continue 
receiving approval for the operation of the sites.  These evaluations have significantly 
contributed to the body of knowledge about SCS (Boyd, 2013).  Although European SCS faced 
opposition, most sites operated legally alongside other service networks (Hedrich et al., 2010).  
As a result, these sites were not required to produce extensive evaluation evidence in order to 
operate like their Australian and Vancouver counterparts.       
 Despite clear findings from MSIC and Insite demonstrating the effectiveness of SIFs, 
both facilities operated for close to ten years without being granted any form of institutional 
legitimacy (Boyd, 2013).  While each site was opposed by their respective governments, the 
                                               
1 An unsanctioned SCS has been operating in the Dr. Peter Centre in Vancouver’s West End neighbourhood since 2002.  The Dr. 
Peter Centre is a residential HIV/AIDs care facility that allows clients to access the supervised consumption services (McNeil, 
Dilley, Guirguis-Younger, Hwang, & Small, 2014).  The site recently received approval from the Liberal government in January 
2016 (Woo, 2016).   
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political battle surrounding Insite has largely shaped the history of SCS in Canada.  In 2003, 
Health Canada granted Insite an exemption from the Controlled Drugs and Substances Act in an 
attempt to counter death and infection from the HIV epidemic in Vancouver’s DTES.  Insite 
continued operating under this exemption until the Conservative government was elected and 
refused to grant a continuing exemption (Cavalieri & Riley, 2012).  With the Conservative 
government threatening to close Insite, site operators took the case to the Supreme Court of 
Canada in 2011.  The court held that closing Insite would violate drug users’ constitutional right 
to life and security of the person (Smith, 2015).  The court stated that there was considerable 
evidence in favour of the SIF decreasing death and disease and little to no evidence that the site 
had a negative impact on public safety.  Therefore, the Supreme Court concluded that under 
these circumstances, the Federal Health Minister should generally grant an exemption (Smith, 
2015).   
 Although Insite was able to remain open, subsequent to the Supreme Court of Canada 
decision the Conservative Federal Government enacted Bill C-2, the Respect for Communities 
Act, that required new supervised injection sites to meet onerous criteria (Smith, 2015).  
Specifically, Bill C-2 undermined the Supreme Court decision by making it exceptionally 
difficult for SCS to be granted an exemption.   Consequently, the restrictive regulatory 
framework governing SCS and these stringent criteria largely prevented the opening of 
additional sites throughout Canada (Boyd, 2013). Nevertheless, in 2015, Canada elected a new 
Liberal government which expressed greater support for harm reduction approaches than their 
predecessors.  Once in office, the Liberals were slow to change existing legislation until the 
dramatic rise in overdose deaths over the course of 2016 forced them to take more immediate 
action (Kirkup, 2016).  In December 2016, the Liberal government announced they were 
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reducing the criteria for opening SCS from twenty-six criteria to five (Zimonjic, 2017).  As a 
result, in February 2017, three SCS in Montreal were approved by Health Canada.  Several 
health authorities (including FH) have now submitted applications for their own sites and are 
awaiting approval from Health Canada.    
 
2.3  Program Justification 
 
2.3.1  Evidence of the effectiveness of supervised consumption sites 
 Abundant evidence supports the effectiveness of SCS from North America, Europe and 
Australia.  Numerous studies have been conducted on facilities throughout Europe, at Insite in 
Vancouver, and at MSIC in Sydney.1 A review of the literature on the effectiveness of SCS 
reveals that the introduction of SCS results in a reduction in overdose deaths, increased referrals 
and entry into detoxification and addiction treatment, reductions in HIV/HCV risk behaviour, 
improved access to medical treatment, health care, and other support services, safer injection 
education and practices, decreased drug-related disorder, and overall cost-savings.  A summary 
of the literature related to each of these benefits is provided below:   
1. Reduction in overdose deaths:  
 In 2011, a study by Marshall, Milloy, Wood, Montaner, & Kerr found a reduction in fatal 
overdose deaths in the vicinity of Insite after the site opened.  During the period before Insite 
opened (Jan 1, 2001, to Sept 20, 2003), researchers examined population-based overdose 
mortality rates within a 500-metre radius of the SIF.  Also, they looked at overdose mortality 
rates during those same periods for the rest of the city.  The study found that the fatal overdose 
rates in the immediate vicinity of Insite decreased by 35% after the site opened.  During the same 
                                               
1
   It is important to note that here have been few thorough impact evaluation studies on European SCS, and the majority of the 
published research from Europe does not currently appear in English (Dolan et al., 2000).  However, the available/accessible 
evidence from Europe is included in the summary of the literature that follows. 
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period, the fatal overdose rates in the rest of the city only decreased by 9.3%.  These findings 
clearly demonstrate that a significant reduction in overdose deaths occurred due to the presence 
of Insite.   
 In addition, studies of Insite and MSIC found staff at both sites managed approximately 
300 overdoses over an 18-month period (Kerr, Tyndall, Lai, Montaner, & Wood, 2006b; MSIC 
Evaluation Committee, 2003).  Researchers estimated that a proportion of the overdoses 
occurring onsite may have been fatal had they occurred elsewhere (there has never been a fatal 
overdose death at Insite or MSIC).  Insite estimated that between March 1, 2004 and July 1, 
2008, eight to fifty-one overdose deaths might have been averted (Milloy, Kerr, Tyndall, 
Montaner & Wood, 2008a).  Similarly, MSIC estimated that between four and nine deaths per 
year of operation may have been averted (MSIC Evaluation Committee, 2003).  As well, one 
European study estimated that the likelihood of staying in the hospital for one night was ten 
times greater for someone who overdosed outside as opposed to someone who overdosed in a 
SCS (Jahresbericht 1996).  Each of these estimates indicates that SCS has helped reduce the 
disability or death that may result from overdose events.  By having trained medical 
professionals onsite to immediately manage overdose events, estimates indicate that several lives 
have been saved.  By analyzing overdose risk behaviour and associated harms, Insite helped 
explain the mechanism through which SCS reduce overdose risk by addressing environmental 
forces (Kerr, Small, Moore, & Wood, 2007b).  People who attended Insite believed they were at 
a reduced risk of fatal overdose because they were able to inject in the presence of medical 
professionals, had time to safely inject without feeling rushed, and were injecting in a safe 
environment without the risk of assault, robbery, or arrest.   
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2. Increased referrals and entry into detoxification and addiction treatment 
 Sites in Europe, Sydney, and Vancouver provided many referrals to their clients for 
detoxification and addiction treatment.  Insite recorded 2,171 referrals to addiction treatment and 
other support services during a one-year period (Tyndall et al., 2006).  In 2003, the MSIC 
Evaluation Committee found that frequent MSIC users were more likely to receive referrals than 
non-frequent MSIC users.  Finally, in several European facilities, findings suggested that clients 
who received referrals at the centres and accessed these referral services experienced 
stabilization or improvement in social functioning and general health (Dolan et al., 2000).  
Therefore, the SCS is an important opportunity to provide referrals to the injection drug user 
population, and staff have been able to successfully connect drug users to meaningful resources 
in their community.   
 Understanding whether or not clients who were referred to treatment at the SCS actually 
entered treatment was another important indicator of the success of SCS facilities.  In Sydney, 
MSIC users were significantly more likely to start treatment and therapy for drug use than non-
MSIC users (MSIC Evaluation Committee, 2003).  Similarly, Insite clients who used the facility 
at least weekly were 1.7 times more likely to enrol in a detoxification program than those clients 
who visited the facility less frequently.  Among the Insite population, 18% began a detoxification 
program during the study period (Wood et al., 2006a).  Researchers at Insite also examined 
detoxification service use after the introduction of the SCS and found a 33% increase in 
detoxification service use in the year after Insite opened compared to the year before 
implementation (Wood et al., 2007).  Insite clients who entered detox were also 1.6 times more 
likely to enrol in methadone treatment and 3.7 times more likely to enrol in other forms of 
addiction treatment.  Finally, individuals who entered detox began attending Insite less 
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frequently in the month after enrolling in detox compared to the month prior.  These findings 
suggest that SCS users who attend the sites more often are not only entering detoxification 
treatment, but may also be successfully decreasing their drug use through these detoxification 
programs. 
3. Reduction in HIV/HCV risk behaviour  
 While there are significant methodological challenges to attributing reductions in blood-
borne viruses directly to SCS, considerable evidence suggests that SCS play a role in reducing 
HIV/HCV risk behaviour.  Several European studies observed reductions in needle sharing and 
increased condom use among clients during the study period (Ronco, Spuhler, Coda, & 
Schopfer, 1996; Jacob et al., 1999).   Insite researchers witnessed similar results with clients 
reducing their likelihood of sharing syringes by 69% during the study period and increasing their 
condom use by 30% (Marshall et al., 2009; Milloy & Wood, 2009).  Also, evidence indicates 
that those clients who accessed medical care from nurses at Insite were more likely to use 
condoms than those who did not (Marshall et al., 2009).  Another study at Insite found more 
consistent use of the SIF was associated with safer injecting practices including decreased reuse 
of syringes, increased use of sterile water, cleaning of injection sites and cooking/filtering of 
drugs (Stoltz et al., 2007).  At the same time, more consistent Insite users were less likely to 
report rushed injections, a behaviour associated with non-sterile injection and increased risk of 
overdose.  These findings highlight how education and supplies provided at the sites help 
promote safe sex and safer injection and ultimately reduce HIV/HCV risk behaviours among 
PWUD.   Clearly, SCS policies prohibiting clients from engaging in risky injection behaviours 
when consuming drugs onsite may lead to further reductions in HIV/HCV risk behaviour and 
translate into behavioural changes offsite (Stoltz et al., 2007).   
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4. Improved access to medical treatment and health care 
 At MSIC and Insite, researchers found that nurses regularly provided care for injection 
related infections and provided referrals for off-site medical treatment (MSIC Evaluation 
Committee, 2003; Small, Wood, Lloyd-Smith, Tyndall, & Kerr, 2008).  The MSIC evaluation 
also found that testing for blood-borne viruses was more common among clients than people 
who did not access MSIC.  As well, one in every four MSIC visits involved the provision of 
health care services, and over 50% of the services provided by staff involved injecting and vein-
care advice.  Finally, interviews conducted with Insite clients revealed that Insite was often seen 
as a preferable venue for seeking medical treatment because the site has long operating hours and 
staff were more experienced caring for PWUD (Small et al., 2008).  As injection related 
infections are one of the leading causes for ER visits and hospitalization among drug users, these 
findings demonstrate that medical treatment offered at the SCS likely reduces emergency room 
visits among PWUD (Kerr et al., 2005c).    
5. Safer consumption education and practices 
 Results from MSIC and Insite evaluations indicate increased use of safer injection 
practices among clients who attend SIFs.  The MSIC Evaluation (2003) found that nearly half of 
MSIC clients reported that their injection practices had become less risky than before they began 
attending the site.  Similarly, 75% of Insite clients reported adopting safer injection practices 
after they began attending the site compared to their injecting practices before (Petrar et al., 
2007).   Interviews with Insite clients found that nurses were providing advice and education 
around safe injection practices in a safe and unhurried environment (Fast, Small, Wood, & Kerr, 
2008), which likely increased knowledge and utilization of safer injection practices.  At the same 
time clients reported that the environment at the facility encouraged them to adopt safer injection 
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practices both onsite and offsite.  The Insite evaluation also compared injection behaviours 
between frequent and non-frequent Insite users as well as Insite clients and non-Insite clients.  
They found that frequent Insite users were 3 times more likely to use sterile water, 2.8 times 
more likely to swab injection sites, 2.8 times more likely to not rush during injections, 2 times 
more likely to dispose of syringes safely, and more than twice as likely not to share syringes than 
non-frequent Insite users (Stoltz et al., 2007).  Finally, Insite clients were 70% less likely to 
inject drugs with a shared syringe than a non-Insite client; nevertheless, prior to Insite opening, 
these same clients were just as likely to use a shared syringe (Kerr, Tyndall, Li, Montaner, & 
Wood, 2005d).  In other words, reduced syringe sharing could be directly attributable to Insite 
attendance and the interventions provided at the facility. 
6. Decreased drug-related disorder 
 Common public concerns with introducing an SCS, such as increases in crime, public 
injection, and injection related litter, have been disproven by studies conducted in Sydney, 
Vancouver, Switzerland, and Germany.  First, research from MSIC and Insite evaluating crime 
before and after site implementation revealed that no increases in crime within the vicinity of 
each SIF occurred (MSIC Evaluation Committee, 2003; Kerr, 2006a).  Additionally, no 
significant changes in drug related activity and loitering in the vicinity of MSIC occurred, 
according to key-informants and police focus groups.  MSIC and Insite counts of improperly 
disposed of syringes and injection related litter decreased after the introduction of each site 
(MSIC Evaluation Committee, 2003; Wood et al., 2004a).  Moreover, testimonies from local 
residents and businesses in Sydney further supported this reduction in injection related litter as 
these groups reported seeing fewer incidents after the site opened.  Finally, reports and counts of 
public injection in Sydney, Vancouver, and across Europe decreased after sites were 
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implemented (MSIC Evaluation Committee, 2003; Wood et al., 2004a; Ronco et al., 1996; 
Kemmesies, 1995).  Also, research from Switzerland and Germany highlighted overall 
reductions in the visibility and public nuisance of the drug scene after sites opened (Ronco et al., 
1996; Kemmesies, 1995).     
7. Estimated cost savings:  
 Reports from MSIC and Insite indicate that significant cost-savings can occur by 
introducing a SCS.  By estimating the associated costs of deaths and disease that are potentially 
averted by the site and accounting for the operational costs of the site, MSIC research suggests 
that the benefits cost-ratio ranges from 1.20 (low estimate) to 1.97 (high estimate) (MSIC 
Evaluation Committee, 2003).  Similarly, researchers from Insite have estimated that the 
program saves $6 million per year of operation (Andresen & Boyd, 2010).   Insite researchers 
conservatively estimated that, on average, Insite prevents 35 new cases of HIV and about 3 
deaths per year (Andresen & Boyd, 2010).  The Insite evaluation estimated that over $18 million 
and 1175 life years are saved by the SIF, reducing the prevalence of HIV and HCV over a ten-
year period (Bayoumi & Zaric, 2008). Therefore, evidence indicates that SCS are an effective 
use of public health spending as they lessen the burden of death and disease related to injection 
drug use thereby reducing costs.     
 
2.3.2 Epidemiological evidence demonstrating the need for SCS in Surrey 
The number of illicit opioid overdose deaths in BC has dramatically increased over the 
past several years.  According to the Coroner’s Service Report (2017), the average number of 
overdose deaths in BC from 1990-2014 was approximately 250 deaths per year.  Nevertheless, as 
indicated in Figure 2.1, the number of illicit overdose deaths rose to 510 deaths in 2015 and that 
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number climbed even more drastically to 922 deaths in 2016 (Coroner’s Service Report, 2017).  
Findings suggest that illicit fentanyl, a potent opioid 100 times more toxic than morphine, is 
responsible for the large increase in illicit drug overdose deaths (see Figure 2.2).  From January 
to November 2016, illicit fentanyl was detected in 60% of drug overdose deaths in BC (BC 
Coroner Service, 2016).  This alarming increase in overdose deaths resulted in provincial health 
officer, Dr. Perry Kendall, declaring a public health emergency in BC on July 27, 2016 
(Government of B.C., 2016).   
 
 
Figure 2.1: Illicit drug overdose deaths by month in BC, 2015-2017 (Coroner’s Service Report, 2017) 
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Figure 2.2: Illicit drug overdose deaths including/excluding fentanyl, 2007-2016 (Coroner’s Service Report, 
2017) 
 
In 2016, the FH Region had the second highest number of illicit drug overdose deaths in 
the province with 310 overdose deaths occurring (approximately 33% of all overdose deaths in 
the province) (Coroner’s Service Report, 2017). Among the FH municipalities, Surrey had the 
highest number of overdose deaths, BC Ambulance Service attendances, and emergency 
department (ED) visits (Coroner’s Service Report, 2017; Patient Care Records data from BC 
Emergency Health Services, 2017; Fraser Health Emergency Department, 2017).  FH 
epidemiological data and data from BC ambulance services show that the problem is most acute 
on 135a Street between 106 and 108 avenues in the area known by locals as “the strip” in the 
Whalley neighbourhood of Surrey.  Similar to Vancouver’s DTES area, the 135a Street area is 
home to a street entrenched population where homelessness, poverty, crime, unemployment, 
mental health issues, and drug use are common challenges.  The nearest hospital to the 135a 
area, Surrey Memorial Hospital (SMH), had 1643 overdose visits in 2016 compared to 170 visits 
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in 2015.  Because many active drug users are admitted to SMH, and are without a safe space to 
use drugs, injection related litter and public injection are regularly reported in and around the 
hospital.  
 
2.4  Program Context 
 
2.4.1  FH Enhanced Overdose Prevention and Response Strategy 
 In response to the opioid overdose crisis, FH launched an Enhanced Overdose Prevention 
and Response Strategy in July 2016.  The strategy includes a variety of actions along the 
prevention to recovery continuum that target different population groups depending on their 
relationship with substance use.  Figure 2.3 summarizes these interventions and the range of 
populations targeted by each service. From left to right across the figure, service level intensity 
increases while the number of people targeted by each intervention decreases. On the left, 
interventions such as community response, education and training target all Fraser Region 
residents and have the largest population health impact.  Such preventative actions can help 
mitigate the impacts of drug use as well as socioeconomic factors contributing to morbidity, 
mortality, and street entrenchment among PWUD (Fischer et al., 2004).  Moving right across the 
figure, interventions specific to substance users such as naloxone distribution, naloxone training 
and detox/daytox with OAT target more mild to moderate substance users.  Finally, treatment 
and recovery services such as residential treatment facilities, supervised consumption services, 
and tertiary treatment target people with severe substance use disorders.  Therefore, the two SCS 
sites are just one of many services being offered by FH to help address the overdose crisis.   
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Figure 2.3: Prevention to recovery continuum (FHA, 2017) 
 
 
 
 
 A description of the specific services in the Enhanced Overdose Prevention and Response 
Strategy are detailed below: 
1. Prevention of drug use and habituation: 
• Creation of intersectoral working group to promote prevention and inform local context 
• Establishment of provincial partnerships to promote opioid safe prescribing guidelines 
• Establishment of communication and outreach efforts with community partners 
• Provision of substance use education at FH facilities and throughout the region 
2. Harm Reduction: 
• Distribution of harm reduction supplies and increased safe needle disposal/collection 
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• Implementation of Supervised Consumption Service(s)  
3. Treatment for Substance Use: 
• Continued operation of the Quibble Creek Sobering & Assessment Centre and Creekside 
Withdrawal Management Centre 
• Expansion of Opioid Agonist Treatment (OAT) across FH facilities and among 
community partners 
• Establishment of residential treatment facilities 
4. Response to overdose events: 
• Training in overdose prevention, recognition, and response education 
• Dispensing Take Home Naloxone (THN) 
• Training on Naloxone Administration for community partners (RCMP, Surrey Fire, etc.), 
PWID, and the general public. 
 
2.4.2 Community Response to Overdose-Crisis  
Within the FH context, the City of Surrey and local RCMP have launched a “City 
Response Plan” to address the overdose crisis and the complex social issues in the 135a 
neighbourhood.  The City of Surrey created the plan to address increased challenges as a result 
of homelessness, mental health issues, and fentanyl use in the 135a area (City of Surrey, n.d.).  
As part of the response plan, the City of Surrey created the Surrey Outreach Team, a group 
focused on enhancing outreach and presence in the 135a street area to increase protections for 
vulnerable populations.  The team includes 12 RCMP officers and 4 by-law officers in the area 
24 hours a day, 7 days a week.  Their goals include targeting those who are preying on 
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vulnerable populations, increasing public safety and security, and connecting those in need with 
addiction and social services.   
In addition, existing community agencies and programs in Surrey continue to provide 
support to the drug using population during this public health crisis.  Lookout Emergency Aid 
Society, a non-profit charity organization, delivers nineteen programs relating to health and 
homelessness in the area.  They operate the Gateway Shelter on 135a Street –a facility offering 
low-barrier services including a free medical clinic, a non-profit dental clinic, mobile harm 
reduction education, harm reduction supplies, outreach activities, a low-cost housing facility, 
peer-distribution of injecting equipment, women specific programming, a high-protein 
supplemental food bank, a community garden and support lounge for individuals affected with 
HIV/AIDS and hepatitis C.  Referrals are also made to various services including primary care, 
mental health, and substance use services and supports.   
Several kilometres from 135a Street and the Gateway Shelter is the Quibble Creek 
Sobering and Assessment Centre (SAC) located on 94a Avenue directly across from SMH.   
While the number of overdose events around Quibble Creek SAC is not as high as 135a Street, 
the site currently provides services to active and recovering users who are able to temporarily 
access the site to safely sober up (maximum stay of 23 hours).  Quibble Creek SAC serves 
individuals who are age 16 and over who are under the influence of alcohol and/or drugs. Several 
other FH services operate within the same building as the Quibble Creek SAC including Surrey 
Substance Use Services, Primary Care Services, and Opiate substitution services (OAT).  In 
close proximity to Quibble Creek SAC, the Creekside Withdrawal Management Centre provides 
detox and withdrawal management services, including long-term supervised withdrawal from 
alcohol and other chemical dependencies, supportive counselling, assessment and referral.  
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2.5  Program Description 
 As of December 2016, FH submitted applications to Health Canada for two supervised 
consumption service sites in Surrey.  Pending approval, these sites have a targeted opening date 
of Spring/Summer 2017.  At both sites, supervised consumption services will be integrated with 
existing health services in the community with the first proposed site being located on 135a 
Street adjacent to the Gateway Shelter and the SHOP Clinic and the second being located in the 
Quibble Creek SAC on 94a Avenue and adjacent to SMH.   A key feature of both proposed sites 
is their integration with existing health services and their provision of OAT.   
 Each site will offer supervised consumptions services –a key component of the provincial 
and regional response to BC’s public health emergency declared last April.  According to the FH 
website, supervised consumption services are “health services where individuals can inject or 
consume [pre-obtained illicit] substances in a hygienic environment under the supervision of 
trained staff, and have opportunities to engage in other health and social services.”  SCS allow 
clients to administer their drugs not only through injection, but orally or intranasally as well.  
The SCS will also offer safer consumption supplies, education on safe injection techniques and 
infection prevention, overdose prevention and intervention, medical and counselling referrals, 
referrals to substance use treatment, housing and other support services.  Naloxone and oxygen 
will be present at both sites for staff to reverse overdoses.   
 The 135a SCS will offer services from a temporary portable adjacent to the Gateway 
Shelter to people consuming injection, oral, or intranasal drugs.  The proximity of the SCS to the 
Gateway Shelter allows for interface between staff at the SCS and shelter, opportunities for 
clients to access nearby (essentially on-site) services, and extra staff support in the case of 
emergency.  The SCS will be open 18 hours a day, 7 days a week.  The site will be staffed with 
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registered nurses and harm reduction workers and operated jointly by both FH and Lookout 
Emergency Aid Society.  When clients first enter the site, they will sign in at the reception desk 
and wait in the waiting area before accessing the consumption area.  The consumption area will 
include seven consumption booths as well as a space for staff and staff washroom.  After clients 
are finished consuming their substances, they will exit the building through a door in the 
consumption area.  However, if clients need to be monitored further, they will remain in the 
temporary portable or will be escorted to the Gateway Shelter.  A detailed floor plan of the 135a 
SCS portable can be found in Appendix A.   
 The Quibble Creek SAC SCS will be accessible to Quibble Creek SAC clients only.  
Once again, FH anticipates the proximity of the SCS to primary care, addiction treatment, and 
mental health services will be beneficial for both clients and staff at the SCS.  The site will be 
open 8 hours a day, 7 days a week with buzz in/ buzz out access to the secured building.  The site 
will be operated by FH and staffed with registered nurses and health care workers with a 
substance use specialization.  The site will be smaller than the 135a SCS with only two 
consumption booths and room for staff supervising the area.  As mentioned previously, this site 
will be located within the Quibble Creek SAC facility and will be restricted to clients who have 
been admitted to the facility.  A detailed floor plan of the Quibble Creek SCS can be found in 
Appendix B. 
 
2.6  Program Objectives 
The short-term objectives for this program include: 
" Increase the knowledge of safe injection among at least 25% of clients by 2018. 
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" Provide a low-barrier, hygienic, safe and supervised injection environment to PWUD in 
the community surrounding each site. 
" Reduce the amount of injection related litter and public injection in the vicinity of each 
SCS by 2018. 
" Ensure all clients have access to safer injection supplies by 2018. 
" Provide referrals to detox or other social services for at least 25% of clients by 2018. 
" Improve stakeholder engagement and buy-in for the program by 10% from baseline by 
2018.   
The medium-term objectives for this program include: 
" Improve the utilization of safer injection practices among 25% of clients who attend the 
site by 2019.   
" Increase the number of referred clients accessing detoxification services or addiction 
treatment (including OAT) to 15% by 2019. 
" Ensure at least 50% of clients are satisfied with SCS services by 2019. 
" Increase stakeholder engagement and buy-in for the program by 25% from baseline by 
2019.   
The long-term objectives for this program include: 
" Reduce the number of overdose deaths among PWUD in the Fraser Region by 2020. 
" Reduce the incidence of infectious diseases among PWUD in the Fraser Region by 2020. 
" Address social issues/determinants (housing, poverty, etc.) through referrals and supports 
among 5% of clients by 2020.  
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2.7  Program Activities 
The activities for this program include: 
" Provide two safe and accepting supervised consumption spaces that offer consumption 
instruction, overdose intervention, and some primary care services 
" Provide safer injection and sex education to clients  
" Provide safe syringe and injection paraphernalia disposal education to clients 
" Provide safer consumption supplies to clients  
" Provide referrals to detox, addiction treatment and other social services  
" Share the evaluation results with stakeholders on an ongoing basis 
" Adapt the program to meet the needs and improve satisfaction of SCS clients 
" Address concerns regarding the site from community residents, businesses, and other 
stakeholders 
 
2.8  Program Stakeholders  
The stakeholders for this program include: 
1. The population who will be accessing the SCS (SCS clients) 
2. PWUD in the vicinity of each site 
3. FH Employees/Organizations 
" FH Senior Executive Committee 
" PPH and MHSU SCS implementation team  
" SCS staff 
4. Community members, partners, or organizations 
" Surrey BIA 
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" Surrey School District 
" RCMP 
" City of Surrey 
" Lookout Emergency Aid Society 
5. Provincial stakeholders: 
" BCCDC 
" Ministry of Health  
" Health Canada 
 
2.9   Program Logic Model 
 Appendix C shows the program logic model for the FH SCS.  The program logic model 
is a simplified schematic which demonstrates the underlying logic for a program.  The logic 
model illustrates the expected pathway or links between inputs, activities, outputs and outcomes.  
This program logic model also shows the target groups that will be the focus of the program 
activities and outcomes as well as the strategies employed to achieve these outcomes.  There are 
specific activities and outcomes for two different target groups in the SCS program.  The first 
target group is the population accessing the SCS (SCS clients).  The second target group includes 
consultation stakeholders (community members, partners, or organizations), FHA Senior 
Executive Committee, and provincial stakeholders.  For the purpose of this logic model, the 
“program” consists of the two SCS that will be implemented (with Health Canada approval).     
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3. Evaluation Methodology 
 
3.1  Evaluation Type 
 This evaluation will be both a process and outcome evaluation.  A process evaluation 
focuses on how a program is implemented/operates and examines whether the program is being 
delivered as intended.  An outcome evaluation determines the extent to which anticipated and 
unanticipated outcomes were achieved and assesses the effectiveness of the program (Patton, 
2010).   
 
3.2  Evaluation Questions 
 Three main evaluation questions, two process and one outcome, are included in this 
evaluation plan.  Each evaluation question has several sub-questions with respective indicators, 
data collection strategies, responsibilities, and timelines.  The evaluation questions, indicators, 
and data collection strategies have been developed in consultations with the FH Senior Executive 
Committee, the SCS implementation team, the Surrey RCMP, the City of Surrey, and the Surrey 
BIA.  Each evaluation question and related sub-question are listed below:   
1. Are the services being provided as intended at the two SCS? (Process) 
i. What is the pattern of client attendance at each SCS?  
ii. Is each SCS providing wound care, vaccinations, and other health services 
onsite? 
2. Are SCS services adapting to client and community needs? (Process) 
i. Have there been any changes to the way SCS services are offered at each site?  
ii. Are clients satisfied with the services offered at each SCS?  
iii. Are community members and key stakeholders supportive of each SCS?  
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3. Are the intended benefits of each SCS being recognized? (Outcome) 
i. Has there been a decrease in OD deaths among PWUD in the vicinity of the 
site? 
ii. Has there been decreased emergency health care utilization among PWUD in 
the vicinity? 
iii. Has there been a reduction in HIV/HCV risk behaviour among clients? 
iv. Has there been increased interest/initiation of accessing detoxification services 
or addiction treatment (including OAT) as a result of referrals from SCS sites? 
v. Has the amount of injection related litter in the area immediately surrounding 
the SCS sites decreased? 
vi. Has the amount of public injection in the area immediately surrounding the SCS 
sites decreased? 
vii. Has the amount of related crime remained the same in the vicinity of each SCS? 
 
3.3  Evaluation Approach 
 The evaluation of the FH SCS will use a utilization-focused approach.  A utilization-
focused approach is based on the principle that an evaluation’s main purpose is to be useful to its 
intended users, and it has two main elements (Patton, 2011): First, the primary users of the 
evaluation must be identified at the beginning of the evaluation process to ensure that their needs 
for the evaluation are defined and clarified. Second, the evaluators must ensure that these 
intended uses will guide every decision made throughout the evaluation process (Patton, 2011).   
 A utilization-focused approach is appropriate for this evaluation, as one of the main goals 
is for stakeholders to have pragmatic results that will allow them to recognize, assess, and 
  45 
respond to site outcomes as the program evolves.  By working closely with stakeholders to 
develop the evaluation plan, the maximum utility and value for FH will hopefully be achieved.  
As SCS are highly controversial, the evaluation must provide evidence that will demonstrate 
whether or not the program is achieving its objectives.  If the program is not meeting its 
objectives, FH will need to be able to use the results to inform decisions and improve the 
performance of the program. Therefore, the primary intended users of the evaluation will 
continue to be engaged in planning and revising the evaluation as the program evolves.  One 
potential drawback to the utilization-focused approach may be the perceived lack of objective or 
independent findings that will result from the evaluation.  However, this limitation will hopefully 
be mitigated through triangulation of the findings using secondary data sources.  
 
3.4  Evaluation Design 
 The proposed evaluation will use a mixed methods approach combining qualitative and 
quantitative data.  The evaluation will also rely on mixed methods to improve validity of the 
findings drawing from the concept of triangulation.  
 
3.5  Methodology from previous evaluations of supervised consumptions sites  
 For the purposes of this evaluation, it is important to replicate the methodology used in 
previous evaluations wherever possible to ensure that comparability is feasible and data 
collection strategies are scientifically based.   Therefore, an extensive review of the literature was 
conducted to examine the indicators measured and data collection strategies used in the 
evaluations of SCS in Vancouver, Sydney, and across Europe.  The literature review was refined 
to examine only those indicators and data collection strategies most relevant to the evaluation 
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questions in the current evaluation.  Due to resource limitations in the current evaluation, an 
analysis of the feasibility of previous evaluation methodology and indicators was also conducted.  
A summary of the methodology used in previous evaluations and the feasibility of these 
strategies for the current evaluation is available in Appendix D.   
 
4.  Data Collection and Analysis 
 
4.1  Evaluation Matrix 
 The evaluation matrix is a key piece of the evaluation, identifying exactly how the 
evaluation questions will be answered in a concise format. The evaluation matrix is included in 
Appendix E, and is an easily adaptable document that can be modified as the program 
progresses to meet the needs of FH and other key stakeholders of the SCS.  Each evaluation 
question and sub-question is described in the matrix along with the respective indicator(s) for 
each question.  The indicators chosen to answer each question also have unique data sources, 
collection methods, timeframes, and associated responsibilities.    
 
4.2  Data Collection Strategies 
 The data collection strategies that will be used to examine the evaluation plan indicators 
are discussed below.  Specifically, a description of each data collection strategy, the deadline for 
data collection activities, and the indicators measured by each data collection tool are outlined in 
detail.  The data collected will be a mix of both quantitative and qualitative data including data 
collected from an access database, clinical notes, surveys, informal interviews, surveillance tools, 
comment cards, and secondary data from the BCCDC, BC Coroner’s Service, RCMP, 
emergency services, and the City of Surrey. These data collection tools are also described in 
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Appendix F at the end of this report.  As mentioned previously, many of these data collection 
strategies and tools are adapted from methodology used in previous evaluations.  
1. Access Database 
Description: An access database will be used at each site to collect intake data and site 
operational data. Client intake data will be minimal to ensure the service is low barrier.  Instead 
of requiring clients to provide their legal name, staff will ask clients to provide a unique “handle” 
or codename upon entry to the site.  This handle will act as an identifier and allow staff to track 
the number of unique clients in the database.  Clients will not be asked for their PHN; however, 
demographic information such as age, gender, and ethnicity will be tracked.  The access database 
will also include space for clinical notes.  This database will be adapted from the database used 
by Insite.  
Deadline: Baseline  
Indicators tracked in access database: 
" demographic information (including age, gender, and ethnicity) 
" # of client visits 
" # of unique clients 
" # of services used by clients 
" # of OD events  
" # of OD events successfully managed onsite 
" # of emergency service calls and attendances to each site 
" # of harm reduction supplies provided 
" # of clients receiving safe injection education 
" # of clients referred to OAT, MHSU and withdrawal management services 
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2. Client Satisfaction Survey 
Description: In-person, interviewer administered, client satisfaction surveys will be administered 
to all SCS clients who agree to participate. Clients of the 135a SCS will be encouraged to 
participate in the survey which will be administered by Lookout staff at the adjacent Gateway 
Shelter. The survey will be administered at the Gateway Shelter because survey administration at 
the SCS would be limited by time, space, and resource constraints.   Clients of the Quibble Creek 
SAC will be administered the survey by staff at Quibble Creek SAC.   
 Clients who complete the survey will receive a small cash incentive ($2 CDN) to 
compensate them for their time.  Participants will also be asked to provide their unique handle on 
the survey and staff should note in the database if clients have completed the survey.  Many of 
the questions from the survey have been adapted from the Insite client satisfaction questionnaire.  
The survey will ask for early feedback from clients at 1 month to facilitate rapid course 
correction if required.  The survey will then be administered again at 6 months once services are 
expected to have stabilized.  The survey administered at 1-month post-implementation is 
attached to this report in Appendix F (7.6.1) and the survey administered at 6-months post-
implementation is attached to this report in Appendix F (7.6.2). 
Deadline:  1 month, 6 months 
Indicators evaluated by client satisfaction survey: 
" # of clients attending the site (frequency)  
" # of referrals from stakeholders to SCS 
" # of clients reporting needle sharing 
" % of clients that report being satisfied with services offered at SCS  
" # of clients receiving safe consumption education from the SCS 
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" # of clients receiving referrals to medical or social services from the SCS 
3. Persons Who Use Drugs in the Community Survey 
Description: A survey will be administered to persons who use drugs (PWUD) in the 
surrounding community of 135a to understand if they are satisfied or dissatisfied with the 
services at the SCS and why.  The PWUD in the community survey will not be administered in 
the vicinity of Quibble Creek SAC as the site will only be accessible to clients. This survey will 
target PWUD who have stopped attending SCS sites (or never attended a SCS) and will be 
administered by Lookout Shelter staff at the Gateway Shelter.  The Gateway Shelter is a 
desirable setting for survey administration because PWUD in the 135a vicinity who do not attend 
the SCS may still visit the shelter.  Also, Lookout staff are more familiar with the population and 
will be able to help recruit PWUD in the community who have stopped or do not attend the site.   
Participants will receive a small cash incentive ($2 CDN) for completing the survey.  There is 
space for participants to provide their unique handle; however, those participants who have not 
attended the site will not have a handle.  Therefore, Lookout staff administering the survey will 
need to be more cautious of tracking who has completed the survey to avoid duplication. Like 
the client satisfaction survey, many of the questions from the survey have been adapted from the 
Insite client satisfaction questionnaire.  The survey will ask for early feedback from PWUD in 
the community at 1 month post SCS implementation to facilitate rapid course correction if 
required.  The survey will then be administered again at 6 months once services are expected to 
have stabilized.  The survey that will be administered at 1-month post-implementation is attached 
to this report in Appendix F (7.6.3) and the survey to be administered at 6-months post-
implementation is attached to this report in Appendix F (7.6.4). 
Deadline:  1 month, 6 months 
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Indicators evaluated by PWUD satisfaction survey: 
" # of PWUD in community who have attended or are attending a site (frequency) 
" # of PWUD in community who have stopped attending a site and the reasons why they 
have stopped 
" # of referrals from stakeholders to SCS  
" # of PWUD in the community reporting needle sharing 
" % of PWUD who report being satisfied with services offered at SCS (if they have 
attended a site) 
" # of PWUD in the who community  have received safe consumption education from the 
SCS (if they have attended a site) 
" # of PWUD in the community who have received referrals to medical or social services 
from the SCS (if they have attended a site).   
4. Community and Business Persons Survey 
Description: A survey will be administered to community members and business-owners in the 
surrounding community of 135a and Quibble Creek SAC.  The survey will examine community 
attitudes and impact of the SCS on businesses and residents as well as perceived changes in the 
neighbourhood as a result of the SCS.  The survey will be available online through 
SurveyMonkey and a link to the survey will be mailed to residents and business persons within a 
500 m radius of each site. The survey administered 1-month pre site implementation is attached 
to this report in Appendix F (7.6.5) and the survey administered at 6 months post site 
implementation is attached to this report in Appendix F (7.6.6). 
Deadline:  1 month (Pre), 6 months (Post) 
Indicators evaluated by Community and business persons survey: 
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" # of community members/business persons who believe the SCS will have a 
positive/negative impact 
" # of community members/business persons reporting public injection 
" # of community member/business persons reporting injection related litter 
" # of community members/business persons who believe various advantages will occur as 
a result of the SCS 
" # of community members/business persons who believe various concerns will occur as a 
result of the SCS 
" % of community members/business persons who are supportive of SCS within vicinity of 
their residence/business 
5. Key Informant Interviews 
Description:  Key informant (qualitative) interviews will be conducted with site managers from 
each SCS and may also be conducted with the SCS implementation and monitoring team.  The 
goal of the key informant interviews is to understand if there have been any changes or should be 
any changes to the way SCS services are offered at each site.  Researchers will use a recording 
device to record the interview, and FH staff will transcribe responses verbatim.  The interviews 
will be conducted with key informants at one-month post site implementation to allow for rapid 
course correction.  The interview will be administered again at 6 months once site operations and 
procedures are expected to have stabilized.  The interview guide is attached to this report in 
Appendix F (7.6.7). 
Deadline:  1 month, 6 months 
Indicators evaluated by key informant interviews with FH staff: 
" # of key informants who believe the sites are operating as intended 
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" # of key informants who believe the sites are achieving their intended outcomes 
" strengths and challenges of each site 
" changes to the way SCS services are offered 
" # of services offered (have services been added/removed?) Why? 
" # of similarities and differences between sites? Why? 
6. Public Injection/Injection Related Litter Tracking Tool 
Description:  Standardized measures of public injection and injection related litter will be 
conducted to examine the impact of the SCS sites on these indicators.  For the purposes of the 
evaluation, public injecting will include any person(s) seen injecting illicit drugs and injection 
related litter will include publicly (improperly) discarded syringes, syringe wrappers, syringe 
caps, sterile water containers, and “cookers”.  The person(s) recording counts will walk through 
the study zone in a similar pattern on each outing and data collection will be structured evenly 
throughout the week.  Tracking will occur at each SCS within an a priori defined geographical 
area in the neighbourhood at a priori-defined times of the week.  The a priori defined 
geographical area for the 135a SCS is defined by the map in Appendix F (7.6.8).  The map 
defining the geographical area for the Quibble Creek SAC is currently being created by an FH 
Epidemiologist.  However, the area that will be included in the study zone will resemble the area 
described by the map in Appendix F (7.6.9).  Each map covers at least a 500-metre radius area 
around each SCS and is divided into zones based on geographical boundaries that confine the 
area.  The zones are also characterized by the frequency of public injection and injection related 
litter that occur within the zone boundaries (see map legend for details).  The 135a zone was 
adapted from the area used in the Lookout Emergency Aid Society’s daily syringe/injection litter 
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collection program called ‘Rig Dig’.  Because Lookout has tracked injection related litter over 
the past year, FH can use their data to triangulate results from the current evaluation.   
 FH has also partnered with Lookout to track injection related litter in the 135a area as 
well as the Quibble Creek SAC area.  The Lookout Rig Dig team will track injection related litter 
by walking through the 135a study zone Mondays, Wednesdays, and Fridays from 9-11 am 
(during Rig Dig).   They will also track injection related litter in the Quibble Creek SAC study 
zone Mondays, Wednesdays, and Fridays from 1-3pm.  Public injection will be tracked 
separately from injection related litter with Mental Health Workers conducting the tracking.  
Mental Health Workers will walk through the Quibble Creek study zone Mondays, Wednesdays, 
and Fridays from 9-11 am to ensure individuals publically injecting are recorded.   Mental Health 
Workers will also track public injection in the 135a study zone on Mondays from 1-3 pm; 
Wednesdays from 3-5 pm; and Fridays from 5-7 pm.  The 135a times for tracking public 
injection are similar to the methodology used in the Insite evaluation.  Public injection is also 
most frequently reported in the afternoons in the 135a vicinity.  Based on the Insite evaluation, 
the largest changes in patterns of public injection and injection related litter will occur within the 
first six weeks of SCS implementation (Wood et al., 2004a).  Therefore, tracking will occur six 
weeks pre SCS implementation and six weeks post.  The tracking tools for recording public 
injection and injection related litter are attached to this report in Appendix F (7.6.10).  
Deadline:  6 weeks pre site opening, 6 weeks post site opening 
Indicators evaluated by public injection/injection related litter tracking: 
" # of people injecting in public before and after site opening 
" # of improperly discarded syringes (or injection related litter) in the vicinity of each SCS 
before and after opening 
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7. Comment Cards 
Description:  Comment cards will also be used to supplement the Client Satisfaction Survey.  
Comment cards will be available at the front desk of each SCS.  Clients will be able to 
anonymously and quickly provide feedback about their satisfaction with the SCS as well as their 
experiences at the SCS.  The comment card format is attached to this report in Appendix F 
(7.6.11). 
Deadline:  Ongoing 
Indicators evaluated by comment cards: 
" % of clients that report being satisfied with services offered at SCS (surveyed onsite) 
" # of clients attending the site (frequency)  
" # of referrals from stakeholders to SCS 
8. Secondary Data Collection 
Description:  For several indicators in the evaluation plan, secondary data will be collected from 
different sources.  FH has requested or obtained access to secondary data from the Coroner’s 
Records, Emergency Services, RCMP, SMH, BCCDC, OAT facilities, MHSU, & Creekside, the 
City of Surrey, and Lookout Emergency Aid Society.  Plans for retrieving this data or partnering 
with sources to collect data have been established.  Table 4.1 provides an overview of the 
secondary data sources, indicators, and deadlines for data collection.   
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Table 4.1: Secondary data sources, indicators, and deadlines overview 
 
 
 
Secondary Data Source Indicators Deadline 
Coroner’s Records  
OR 
Emergency Services 
(Ambulance, Fire, RCMP) 
# of OD deaths in vicinity before 
and after site opening (500m) 
 
Baseline, monthly 
Emergency services 
(Ambulance, Fire, RCMP) 
# of emergency service calls and 
attendances 
Baseline, weekly 
Emergency services 
(Ambulance, Fire, RCMP) 
records of transport  
OR 
SMH records of OD patients 
# of related ED presentations from 
vicinity of SCS (500m) 
Baseline, weekly 
BCCDC Take Home 
Naloxone (THN) Kit 
reporting 
# of THN kits provided onsite 6 months; will be 
retrospective and 
include all distribution 
since opening 
OAT facilities intake 
questionnaire 
# of clients accessing OAT Baseline, 6 months 
OAT facilities database(s) # of clients who are accessing 
OAT actually starting OAT 
Baseline, 6 months 
MHSU & Creekside 
databases 
# of clients requesting/accessing 
withdrawal management services, 
mental health services, and MHSU 
services 
Baseline, 6 months 
City of Surrey Works Yard # of complaint calls related to 
injection litter 
6 weeks pre/6 weeks 
post for triangulation 
with injection related 
litter tracking 
City of Surrey  
 
# of complaint calls related to 
public injection 
6 weeks pre/6 weeks 
post  for triangulation 
with public injection 
tracking 
Lookout Emergency Aid 
Society ‘Rig Dig’ tracking 
# of improperly discarded syringes 
and injection related litter 
 
1 year pre/1 year post 
for triangulation with 
injection related litter 
tracking 
RCMP (RMS data) # of crimes committed in the 
vicinity (crimes include drug 
trafficking, assaults and robberies, 
and vehicle break-ins and vehicle 
theft in the 500-metre radius of the 
site) 
12 months pre, 12 
months post  
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4.3 Data Analysis Methods 
 The evaluation will use a combination of quantitative and qualitative data analysis 
methods to analyze findings.  The goal of the analysis is to answer each evaluation question in 
order to understand if each SCS is meeting targeted program objectives.  A detailed overview of 
the data analysis plan for each data collection strategy is outlined below: 
1. Access Database: 
 Data from the access database (with the exception of clinical notes) will be analyzed 
using quantitative data analysis methods.  The number of client visits, frequency of client visits, 
services used by clients, client demographic information, as well as the number of OD events, 
emergency service calls, emergency service attendances to each site, injection education, 
referrals and harm reduction supplies provided will be counted using data analysis software such 
as Excel or Statistical Analysis Software (SAS).  A frequency distribution for each indicator will 
be created as well as measures of central tendency and dispersion (descriptive statistics).  
Monthly frequency distributions will be helpful in exploring each of the indicators tracked in the 
access database.  The data will also be disaggregated across different variables and subcategories 
of variables to explore patterns.  For example, client demographic characteristics may be 
disaggregated to examine various indicators for specific population groups.  Access database 
findings will be important for understanding a range of evaluation questions (client attendance, 
OD deaths, emergency health care utilization, HIV/HCV risk behaviour, and referrals); therefore, 
analysis will be ongoing to produce findings for stakeholders on a regular basis.   
2. Client Satisfaction and PWUD in the Community Surveys 
 Survey data from the closed-ended questions in the Client Satisfaction Survey and the 
PWUD in the Community Survey will be inputted into Excel or SAS and analyzed using the 
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quantitative methods described above.   Closed ended survey questions among clients/PWUD in 
the community will help identify how participants are being referred to the sites, how many are 
sharing injection equipment, how many are receiving safe consumption education, how many are 
receiving referrals to medical or social services from the SCS, and how many are satisfied with 
the SCS.  Results from both surveys will be compared using significance testing to analyze any 
differences between client and non-client responses.  Results from surveys administered at 1 
month and 6 months post site implementation as well as surveys from different SCS facilities 
will also be compared.   
 Depending on the number of open-ended survey question responses, data will be inputted 
into Microsoft Word or qualitative analysis software such as NVivo11.  Because qualitative data 
from the surveys will likely be limited, Microsoft Word may be sufficient.  According to LaPelle 
(2004), Microsoft Word is a suitable and efficient alternative to qualitative data analysis software 
when working with basic qualitative data.  Once data is inputted into Microsoft Word or 
NVivo11, survey questions will undergo thematic content analysis to help identify salient issues 
and typical responses among the participants.  Green and Thorogood (2014) cite thematic content 
analysis as the most common approach used in qualitative data analysis and characterize it as an 
effective stand-alone method for presenting the key elements of participant responses.  Using an 
inductive coding approach, key themes will be identified as the data is analyzed.  Emerging 
themes could provide useful findings on the impact and effectiveness of the SCS as well as SCS 
satisfaction among clients/PWUD in the community.  
3. The Community & Business Persons Survey 
 The results from the Community & Business Persons Survey will be stored in 
SurveyMonkey.  Therefore, these results will either be analyzed directly in SurveyMonkey using 
  58 
features within the online survey provider, or the data may be exported and analyzed in Excel.  
Survey responses will be analyzed using both quantitative and qualitative data analysis methods 
similar to the client/PWUD surveys.   Significance testing between the pre and post surveys as 
well as 135a versus Quibble Creek vicinity respondents will be important for answering several 
evaluation questions.   Significant differences in perceived impact of SCS, support for SCS, 
advantages or concerns around SCS, and public injection and injection related litter reporting pre 
and post site implementation could indicate that the SCS is influencing community and business 
persons’ support towards the SCS and impacting public order.  Finally, differences between 135a 
versus Quibble Creek vicinity respondents could provide opportunities for program adaptations 
or interventions specific to each SCS site.   
4. Key Informant Interviews 
 Transcripts from key informant interviews will be imported into NVivo11 for thematic 
content analysis.  The interview data will also be coded using an inductive coding approach to 
allow for new themes to emerge.  Key themes that emerge from the qualitative interviews will be 
extremely useful for assessing several process evaluation question indicators such as changes to 
the way SCS services are offered, differences between services at each SCS site, and strengths 
and weaknesses of each SCS site.  By conducting key informant interviews as early as 1 month 
post site implementation, findings from the analysis will allow FH to change program activities 
or operations to help address any issues specific to each SCS.   
5. Public Injection/Injection Related Litter Tracking 
 Analysis of tracking data for public injection and injection related litter will be analogous 
to the data analysis methods used by Wood et al. (2004a) in their analysis of public order 
pre/post Insite implementation.  In SAS, descriptive statistics and stratified linear regression 
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models will be used to compare public injection and injection related litter counts pre and post 
site implementation.  Similar quantitative data analysis methods will be used to analyze 
secondary data related to public order tracking such as data from the Lookout Emergency Aid 
Society ‘Rig Dig’ tracking, City of Surrey, City of Surrey Works Yard, and the Community and 
Business Persons Survey.  Findings from secondary data will be important for triangulation of 
public order data to further support the validity of the evaluation.  As improvements in public 
order are a key interest of many SCS evaluation stakeholder groups, providing significant 
evidence demonstrating the impact of the SCS sites on these indicators will be critical.    
6. Comment Cards 
 Comment cards will be analyzed using the same methods as the client/PWUD in the 
community surveys.  Once again, Microsoft Word should suffice given the limited amount of 
qualitative data that will be examined.  Findings from comment cards will help triangulate 
evidence from the client satisfaction surveys around SCS satisfaction, attendance, and referrals.  
The open-ended question on the comment card could also provide important insights pertaining 
to these indicators.   
7. Secondary Data Collection 
 Several evaluation questions rely on the analysis of secondary data to be answered: 
" First, the number of overdose deaths occurring in the years pre and post SCS 
implementation within a 500-metre radius of the sites will be analyzed using data from 
Coroners’ Records.  Using SAS, mortality rates will be stratified by proximity to the 
SCS during the one-year period pre-SCS and post-SCS implementation.  Sensitivity 
analyses similar to those conducted in Marshall et al. (2011) will be conducted to assess 
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the significance of the findings. Findings from the analysis will help determine the 
impact of the SCS on overdoses within the 135a and Quibble Creek areas. 
" Data for drug-related emergency service calls and attendances as well as drug related 
ED presentations from within the vicinity of the SCS will be analyzed using similar 
methods to those used to assess the SCS impact on overdose deaths.     
" The BCCDC THN kit reporting data will be retrospectively analyzed at six months post 
site implementation to see if the distribution of THN kits has increased in the vicinity of 
the sites.    
" Data from intake questionnaires and databases at facilities offering OAT as well as 
MHSU and Creekside Withdrawal Management Services will be examined at baseline 
and post site implementation to understand if increases occur in the number of drug 
users accessing addiction treatment services resulting from referrals from the SCS.  Data 
will be inputted into SAS, and significance testing will determine if the SCS has had 
any impact on entry into substitution therapies or addiction treatment. 
" Secondary data related to public order will be obtained from the City of Surrey Works 
Yard, City of Surrey, and Lookout Emergency Aid Society.  The analysis methods were 
outlined previously under the public injection/injection related litter analysis section. 
" Finally, RCMP crime statistics for charges involving drug trafficking (which is defined 
to include selling, administering, giving, transferring, transporting, sending, or 
delivering illicit drugs), assaults and robberies, and vehicle break-ins and vehicle theft 
in the 500-metre radius of the site will be analyzed to understand the SCS impact on 
crime in the area.  The analysis methods will be similar to those used by Wood et al. 
(2006b) in their analysis of crime in the vicinity of Insite.  Crude monthly crime totals 
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for one-year period pre SCS and post SCS implementation will be compared using SAS.  
A t-test will be used to understand if any significant differences are apparent in overall 
crime as well as each type of crime pre and post site implementation.   
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4.4 Timeline 
Component: Primary Data Collection Lead Timeline (months) 
3pre 2pre 1pre 
Si
te
 Im
pl
em
en
ta
tio
n 
1 2 3 4 5 6 7 8 9 10 11 12 
Conduct pre-implementation walk around 
using tracking tool to examine injection 
related litter & public injection 
FH staff 
or RA 
               
Administer Community and Business Persons 
Survey (send survey invite in mail with online 
link) 
FH 
staff- 
Amy  
               
Create Access Database and train staff in 
database use for ongoing collection 
Chris    
Ongoing collection of data in access database 
Provide each site with comment cards and box 
to collect submitted feedback  
FH staff    
Ongoing collection of client feedback from comment cards 
Conduct key informant interviews to 
understand SCS services/changes (conduct 
interviews, transcribe, analyze findings and 
produce report) 
Rachel                
Client Satisfaction Survey (administer 
questionnaire, analyze findings, produce 
report) 
Lookout 
staff, 
Rachel 
               
PWUD in Community Satisfaction Survey 
(administer survey, analyze findings, produce 
report) 
Lookout 
staff, 
Rachel 
               
Component: Secondary Data Collection 
Collect RCMP crime data (*Data may be 
collected 12 months pre/12 months post) 
FH staff, 
Arjen 
   
Si
te
 Im
pl
em
en
ta
tio
n 
            
Track City of Surrey complaint calls regarding 
public order (injection related litter and public 
injection) 
FH staff, 
City of 
Surrey 
               
Obtain EHS data on # of emergency calls, 
attendances, and ED presentations from 
vicinity of each SCS 
Salman 
& 
Shovita 
   
Baseline, weekly data collection 
Obtain SMH data on ED presentations from 
vicinity of each SCS 
Salman    
Baseline, weekly data collection 
Obtain Coroner’s records or EHS data on the # 
of OD deaths in vicinity 
Salman    Pre, Baseline, monthly data collection 
Collect data on # of clients accessing and/or 
attending OAT, MHSU, & Creekside services 
FH staff                
Obtain BCCDC data reporting # of THN kits 
distributed from each SCS  
FH staff                
Table 4.2: Timeline for data collection activities 
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4.5 Respondent Burden for Data Collection 
Description:  Providing an overview of the respondent burden for data collection is part of the utilization focused approach of this 
evaluation.  The evaluation recognizes the time commitment from various groups (especially clinical staff and clients) and this 
overview provides an opportunity to understand whether these expectations are feasible for respondents.   
 
Respondent Group Data Collection Requirements Frequency of Collection Estimated time to 
complete (if 
available) 
Program participants Comment Card 
Client Satisfaction Survey 
Ongoing (optional) 
1 month, 6 months 
2 minutes 
5-10 minutes 
People who use drugs 
(PWUD) in the 
community 
PWUD in the Community Survey 1 month, 6 months 5-10 minutes 
Community & Business 
Persons 
Community & Business Persons Survey 1 month pre, 6 months post 5-10 minutes 
Program staff Access database Ongoing 5 minutes per client 
visit 
Site manager Key informant interviews Baseline, 6 months 15 minutes per 
interview 
Fraser Health Staff Mail link for Community and Business Persons 
Survey 
Collect treatment services data from (MHSU, OAT, 
& Creekside) 
Baseline, 6 months 
Baseline, 6 months 
Unknown 
Unknown 
Lookout Staff Administer Client Satisfaction and PWUD in 
Community Survey 
1 month, 6 months 5-10 minutes 
City of Surrey Complaint call tracking (public injection/related 
litter) 
3 months pre, 6 months post Unknown 
RCMP Crime data collection from RMS records 12 months pre/post Unknown 
BCCDC THN kit data (# distributed from SCS) 3 months pre, 6 months post Unknown 
Epidemiologist EHS data for calls and attendances from SCS 
Coroner’s Data/EHS data on OD deaths 
SMH data on OD presentations in ED from vicinity 
of SCS 
 
Baseline, weekly 
Baseline, monthly 
Baseline, weekly 
Unknown 
Unknown 
Unknown 
Table 4.3: Respondent burden for data collection 
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5. Communications Plan 
 
 Sharing the evaluation findings with the primary and secondary intended users of 
the evaluation will be critical.  Given the controversial nature of SCS, several 
stakeholders will have questions and concerns that may be answered by the evaluation 
findings.  Consequently, it is important that FH disseminate these findings in a clear and 
transparent manner to all stakeholders as well as the general public.   
 Therefore, a report will be prepared by the Evaluation Specialist to share the 
results of the evaluation with primary and secondary intended users of the evaluation.  A 
summary of the report (briefing document) will also be developed to ensure key findings 
from the evaluation are shared in a more concise and accessible way to intended users.   
Additionally, evaluation findings may be summarized in a presentation to be delivered to 
FH employees, community members, and other stakeholders.  The evaluation results will 
also be shared on the FH website alongside their existing information on SCS.  The 
website will be an opportune place to include more interactive dissemination methods 
such as infographics outlining key findings to the public.  Finally, the evaluation findings 
may be communicated in FH press briefings or news releases to stakeholders and the 
public.     
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7. Appendices 
 
7.1 Appendix A: Floor Plan for 135a SCS 
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7.2 Appendix B: Floor Plan for Quibble Creek SAC SCS 
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7.3 Appendix C: Program Logic Model 
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#	overdose	events	
#	overdose	events	treated	successfully	
#	clients	monitored	aVer	SCS	use	
Service	Plan/SCS	policies	developed	
Database	developed	
#	staﬀ	hired	and		trained	
#	of	stakeholders	receiving	updates		
Development	of	media	campaign	
#	open	houses	conducted	
SCS	informa)on	available	to	public	
#	of	spokespeople	trained	
#	of	partnership	agreements	est.	
100%	of	key	stakeholders	consulted		
#	of	aWendees	in	open	houses		
Community	Advisory	CommiWee	est.		
Short-term	outcomes	(year	1)	 Medium-term	outcomes	(year	2-3)	 Long-term	outcomes	(year	4-5)	
Improved	access	to	wound	care/imms.	
Increased	number	of	clients	referred	to	
OAT/other	services	and	supports		
Increased	knowledge	and	a^tudes	
around	safe	injec)ng	prac)ces	
	
Increased	knowledge	and	awareness	of	
safe	syringe	use	and	disposal	
	
Increased	knowledge	in	peer	overdose	
Increased	access	to	HR	supplies	
Target	popula)on	aWending	sites	
OD	events	successfully	managed	onsite	 Reduc)on	in	number	of	OD	deaths	in	
vicinity	of	sites	
SCS	best	prac)ces	implemented	at	sites	
Site	policies/rules	enforced	
Improved	engagement	and	buy-in	from	
stakeholders	;	partnership	agreements	
established	
		
Stakeholders	and	the	public	are	well	
informed	about	the	services	oﬀered	at	
the	site	and	intended	beneﬁts		
Findings	from	evalua)ons	of	the	SCS	are	
communicated	to	stakeholders	and	the	
public	
Spokespeople	for	the	site	communicate	
eﬀec)vely	with	the	media	
Reduc)on	in	HIV,	HCV,	and	overdose	
risk	behaviour	and	improved/safer	
injec)on	prac)ces	on	and	oﬀsite	
	
Increased	number	of	clients	accessing	
OAT/other	services	and	supports	
Increased	in	help	seeking	behaviour	
Reduc)on	in	amount	of	injec)on	
related	liWer	
Decreased	public	injec)ng	
Increased	use	of	safe	injec)on	supplies	
and	reduc)on	in	needle	sharing	
Rapid	response	protocol	and	
procedures	followed	by	staﬀ		
	
Clients	aware	and	adhere	to	site	
policies/rules	
	
Decreased	drug	use	in	region	
Decreased	prevalence	of	infec)ous	
diseases	among	drug	using	pop.	
	
Cost	savings	from	reduced	use	of	OD	
related	emergency	services/
hospitaliza)ons		
	
Increased	social	integra)on	of	clients	
Clients	sa)sﬁed	with	services	oﬀered	
Reduc)on	in	number	of	OD	deaths	
across	region	
	
Ongoing	eﬀec)ve	opera)on	of	services	
Enhanced	capacity	to	manage	incidents	
Injec)on	related	liWer	and	public	
injec)ng	minimal	
	
Stakeholders	increasingly	involved	in	
planning	and	opera)on	of	site	;	
Regular	partner	mee)ngs	held	
		
Stakeholders	take	an	ac)ve	role	in	
encouraging	use	of	the	site	(i.e.	RCMP	
refer	clients	to	SCS)	and	promo)ng	site	
		
SCS	opera)ons	are	adjusted	or	moved	
based	on	evalua)on	ﬁndings	
SCS	is	portrayed	in	a	posi)ve	light	in	
the	media	and	throughout	the	
community 	 		
	
SCS	follows	best	prac)ces	and	delivers	
on	intended	outcomes3	
SCS	aligns	with	health	and	community	
goals	
Increasing	public	support	for	and	
acceptance	of	SCS	
	
1:	Referrals	to	other	services	and	supports	include:	withdrawal	management	services,	mental	health	services,	MHSU	services	
2:	Safer	consump)on	educa)on	includes:	how	to	use	the	consump)on	equipment,	proper	consump)on	techniques,	overdose	preven)on	and	response	educa)on	(incl.	CPR),	disposal	of	drug	use	equipment	
3:	Intended	outcomes=	1]Preven)on	of	OD	deaths	2]Reduc)on	of	HIV/HCV	risk	behaviour	3]	Increased	ini)a)on	of	substance	use	treatment	4]reduc)on	in	injec)on-related	liWer	5]	No	increase	in	drug	use	or	related	crime	6]	Cost	savings	to	the	health	care	system	7]	Reduc)on	in	public	injec)ons		
  
7.4 Appendix D: Evidence Summary of SCS Evaluation Methodology  
 
Evidence Summary of SCS Evaluation Methodology 
 
 
Evaluation Question #1: Are the services being provided as intended at the two SCS and adapting to client and community needs? (process evaluation) 
 
Sub-evaluation 
questions 
Literature Site Location Methodology/Indicators Data Source Feasibility 
for FH SCS 
(*) 
i. What is the 
pattern of client 
attendance at each 
SCS? 
Tyndall et al. 
(2006) 
 
Insite, 
Vancouver 
• Used database and handles to track unique client visits over a one year 
period 
• Tracked how often individual clients were using the SIF 
 
SIF clients * 
Kimber et al. 
(2008) 
 
MSIC, Sydney • Used surveillance data from SIF, post codes from the needle syringe 
sharing program and the Australian bureau of statistics to estimate 
number of IDUs in the area 
• Then used prevalence estimation methods  (capture histories, Poisson 
estimates) to calculate the percentage of IDUs using the site 
IDU 
population 
within 2 km 
radius of site 
* 
Dubois-Arber et al. 
(2008) 
Drug 
Consumption 
Room (DCR), 
Geneva, 
Switzerland 
• Recorded injection profiles and DCR use by PWID 
• Two sources of routine data were used: data collected at the first visit 
by any new client (entry questionnaire) and data collected on the 
substances injected at each visit to the DCR 
• A typology of injection profiles was constructed 
• Associations between injection characteristics and drug consumption 
patterns were examined 
 
PWID at DCR * 
ii.  Is each SCS 
providing wound 
care, vaccinations, 
and other health 
services onsite? 
Lloyd-Smith et al. 
(2010) 
Insite 
Vancouver 
• Measured factors associated with hospitalization due to cutaneous 
infection or other cutaneous complications as a result of injection 
• Measured prevalence among SIF users over a one year period  
SEOSI cohort * 
McNeil et al. 
(2014) 
Dr. Peter 
Centre (DPC) 
• Qualitative interviews conducted with 13 DPC residents between 2010-
2011  
• Interviewed participants to find out how DPC Residence’s model of 
care (a) shaped healthcare access, (b) influenced healthcare interactions 
and (c) impacted drug use practices and overall health  
 
 
 
 
13 DPC 
residents 
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Evaluation Question #2: Are SCS services adapting to client and community needs? (process evaluation) 
 
Sub-Evaluation 
Questions 
Literature Site Location Methodology/Indicators Data Source Feasibility 
for FH SCS 
(*) 
i. Have there been 
any changes to the 
way SCS services 
are offered at 
each site? 
No available evidence found in the literature 
ii. Are clients 
satisfied with the 
services offered at 
each SCS? 
Wood et al. (2004b) 
 
Insite, 
Vancouver 
• Assessed client satisfaction with services offered at the SIF by 
administering a survey 
• Clients rated service quality in terms of the 5 SERVQUAL dimensions  
SEOSI cohort * 
Small et al. (2011a) Insite, 
Vancouver 
• This study involved 50 semi-structured qualitative interviews exploring 
the IDU perspectives on the design and operation of the SIF  
• Interview encouraged discussion of the design and operation of the SIF 
and potential barriers to accessing the SIF 
SEOSI cohort  
Small et al. (2009) Insite, 
Vancouver 
• 50 semi-structured qualitative interviews were conducted 
• Interviews examined IDU perspectives regarding the impact of SIF use 
on access to health and social services. 
• Specifically, the SIS’s impact on access to care and treatment of 
infections following injection 
SEOSI cohort  
Small et al. (2012) Insite, 
Vancouver 
• Qualitatively examined the motivations of IDUs to attend Vancouver’s 
SIF 
• Motivations included: seeking safety, receiving sterile equipment and 
adequate care in case of overdose 
SEOSI cohort  
Petrar et al. (2007) Insite, 
Vancouver 
• Evaluated IDU satisfaction with SIS 
• Participants were surveyed about their experiences and beliefs around 
the SIF. 
• Examined injecting behavior (changes in injecting behavior): syringe 
disposal, public injecting, and safer injecting.   
• Also examined common factors limiting IDU’s use of the SIF: travel to 
SIF, operating hours, waiting times to access SIF 
• Finally, examined ways which SIF could be improved from IDU 
perspective: longer hours, addition of washrooms, and reduced waiting 
times.  
SEOSI cohort * 
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iii.  Are 
community 
members and key 
stakeholders 
supportive of each 
SCS? 
 
 
 
DeBeck et al. 
(2008) 
Insite, 
Vancouver 
• Examined impact of local police on SIS attendance 
• Tracked referrals to SCS by police  
• Also tracked number of IDUs who had heard about SCS from police 
SEOSI cohort * 
Salmon et al.( 
2007) 
MSIC, Sydney • Computer assisted telephone interviews were conducted among random 
samples of residents and business operators in Kings Cross before and 
after opening of SIF 
• Data collection included socio-demographic characteristics (of 
residential respondents only), perceptions of drug-related public 
amenity issues in the local area, and perceived advantages and 
disadvantages of MSIC 
Local 
residents: 540–
326 business 
operators: 
269–210 
* 
Wood et al. (2004b)  
 
Insite, 
Vancouver 
• Conducted a community survey (administered in-person) 
Recorded perceived changes in the neighbourhood after the SIF’s 
opening from residents and businesses 
Street recruited 
residents and 
street level 
businesses 
* 
 
 
Evaluation Question #3: Are the intended benefits of each SCS being recognized? (Outcome evaluation question) 
Sub-evaluation 
Questions Literature Site Location Methodology/Indicators Data Source 
Feasibility for 
FH SCS (*) 
i.  Has there been 
a decrease in OD 
deaths among 
clients? 
Kerr et al. (2006b) Insite, 
Vancouver 
• Examined # overdoses/overdose deaths at site 
• Examined the drugs used prior to each overdose event and the clinical 
features of the overdoses that occurred 
• Examined the interventions undertaken by staff in response to these 
overdoses.  
 
SEOSI cohort * 
Kerr et al. (2007b) Insite, 
Vancouver 
• Semi-structured qualitative interviews  
• Examined IDU accounts of overdose 
• Examined perspectives regarding the impact of SIF use on overdose risk 
and experiences of overdoses 
• Assessed environmental factors that drive high rates of overdose among 
IDUs 
SEOSI (50 
interviews) 
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Marshall et al. 
(2011) 
Insite, 
Vancouver 
• Examined population-based overdose mortality rates for the period 
before and after the opening of the Vancouver SIF.  
• Compared overdose fatality rates within an a priori specified 500 m 
radius of the SIF and for the rest of the city. 
Coroner’s 
records * 
Milloy et al. 
(2008a) 
Insite, 
Vancouver 
• Tracked OD events within last six months from baseline throughout the 
study period 
• Evaluated whether the SIF had impact on # of OD events 
SEOSI cohort * 
Milloy et al. 
(2008b) 
Insite, 
Vancouver 
• Estimated the number of fatal overdose deaths by measuring the number 
of deaths potentially prevented at the SIF (defined as events within the 
SIF that required the provision of naloxone, a 911 call or an ambulance)  
• Inputs were derived from counts of overdose deaths by the British 
Columbia Vital Statistics Agency and non-fatal overdose rates from 
published estimates.  
Data from BC 
vital statistics 
agency and 
data from 
Insite 
 
Van Beek et al. 
(2004) 
MSIC, Sydney • Examined incidence of OD  
• Examined # of deaths 
• Examined characteristics of clients that OD 
• Examined care of overdoses (oxygen vs. naloxone, support time).  
3747 MSIC 
site users * 
ii.  Has there been 
decreased 
emergency health 
care utilization? 
Kerr et al. (2006a) 
 
Insite, 
Vancouver 
 
• Recorded the # of OD events successfully managed within the SIF 
through the provision of oxygen by staff 
• Anticipate significant cost savings result from onsite response 
 
 
SEOSI 
 
* 
Small et al. (2008) 
 
Insite, 
Vancouver 
 
• Data from 50 in-depth qualitative interviews conducted 2005-2006 
• Interviews explored themes relating to SIF use and its impact on 
managing injection-related infections and the effects of specialized and 
onsite related care 
 
SEOSI 
 
 
Salmon et al. 
(2010) 
MSIC, Sydney • Examined the number of ambulance attendances before and after the 
opening of the SIF 
• Examined the number of calls to emergency services during the open 
hours of the SIF in the vicinity of the SIF (1.5km2) 
 
Ambulance 
records on all 
patients 
treated from 
1998-2006 
* 
Jozaghi, et al. 
(2013) 
Montreal  • Conducted a cost-benefits and cost-effectiveness analysis of reduced 
HIV/HCV as a result of implementing a SIF in Montreal using 
mathematical modeling  
• Determined net average benefit-cost ratio for both HIV/HCV and for 
each SIF added 
Analyzed 
secondary data 
from Insite 
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Andresen & Boyd 
(2010) 
Insite, 
Vancouver 
• Used mathematical modeling to estimate the number of new HIV 
infections and deaths prevented each year by SIF  
• Included new HIV infections and deaths prevented, in conjunction with 
estimated lifetime public health care costs of a new HIV infection, and 
the value of a life, to calculate a portion of the societal benefits of Insite.  
• This social benefit is weighed against cost of SIF 
Analyzed 
secondary data 
from Insite 
 
iii.  Has there 
been a reduction 
in HIV/HCV risk 
behavior? 
Kerr et al. (2005d) 
 
Insite, 
Vancouver 
 
• Compared syringe sharing between consistent SIF users with a 
community-recruited sample of injection drug users 
• Both groups had similar rates of syringe sharing before the facility 
opened 
 
VIDUS (431 
participants)  
 
 
Stoltz et al. (2007) Insite, 
Vancouver 
 
• Consistent SIF users were compared with inconsistent SIF users on self-
reported changes in injecting practice behaviours 
• Behaviours included reuse of syringes, use of sterile water, swabbing 
injection sites, cooking/filtering drugs, rushed injections, safe syringe 
disposal and public injecting 
SEOSI cohort * 
Salmon et al. 
(2009) 
MSIC, Sydney • Measured how many IDUs had been tested for HIV compared to other 
Australian cohorts who were not attending SIF 
• Used self-reported prevalence of HIV testing and associated factors 
among cohort between 2001 and 2007 
MSIC users 
(exhaustive 
population) 
 
Milloy et al. (2009) Insite, 
Vancouver 
• Examined the impact of Insite on syringe sharing 
• Used data from all available peer-reviewed estimates of syringe sharing 
at Insite to construct a random-effects meta-analysis model to produce a 
pooled estimate of the relationship between SIF use and syringe 
sharing. 
Findings from 
relevant 
studies  
 
iv.  Has there been 
increased 
interest/initiation 
of accessing 
detoxification 
services or 
addiction 
treatment 
(including OAT) 
as a result of 
referrals from 
DeBeck et al. 
(2010) 
Insite, 
Vancouver 
 
• Administered questionnaire at baseline and subsequent follow-up visits 
• Examined role of SIF in entry into detox program and injection 
cessation (a period of at least six months without injecting) 
SEOSI cohort 
 * 
Wood et al. (2006a) 
 
Insite, 
Vancouver 
 
• Examined correlation between SIF use and entry into detox program 
over 2 year period 
• Frequency of SIF attendance and characteristics of IDU examined 
 
 
SEOSI cohort * 
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SCS sites? Wood et al. (2007) 
 
Insite, 
Vancouver 
• Conducted retrospective and prospective database linkages with 
residential detoxification facilities and used generalized estimating 
equation (GEE) methods to examine the rate of detoxification service 
use among SIF participant 
• Analyzed the year before versus the year after the SIF opened 
 
SEOSI cohort  
McNeil et al. 
(2014) 
Dr. Peter 
Centre (DPC) 
• Qualitative interviews conducted with 13 DPC residents between 2010-
2011  
• Interviewed participants to find out how DPC Residence’s model of 
care (a) shaped healthcare access, (b) influenced healthcare interactions 
and (c) impacted drug use practices and overall health  
13 DPC 
residents * 
v.  Has the 
amount of 
injection-related 
litter in the area 
immediately 
surrounding the 
SCS sites 
decreased? 
Wood et al. (2004a) 
 
Insite, 
Vancouver 
• Measured public order indicators (including injection related litter) 
within defined times of the week pre/post site implementation.   
• Data collection involved walking through the study zone in the same 
pattern.   
• Measures of discarded syringes, injection-related litter, and public 
injection drug use are all measured prospectively 
• Also measured # of used needles discarded in public disposal boxes 
Surrounding 
area of SIF * 
vi.  Has the 
amount of public 
injection in the 
area immediately 
surrounding the 
SCS sites 
decreased? 
 
Wood et al. (2004a) 
 
Insite, 
Vancouver 
• Measured specified public order indicators within an a priori defined 
times of the week.   
• Data collection involved walking through the study zone in the same 
pattern.   
• # of discarded syringes, injection-related litter, and public injection drug 
use were all measured prospectively.   
Surrounding 
area of SIF * 
McKnight et al. 
(2007) 
Insite, 
Vancouver 
• Examined characteristics and factors associated with public injection 
including frequency of SIF use and the impact on public injection  
SEOSI cohort * 
vii.  Has the 
amount of related 
crime remained 
the same in the 
vicinity of each 
SCS? 
 
Kerr et al. (2006b) 
 
 
Insite, 
Vancouver 
• Drug use behaviours were observed in the one-year period before the 
opening of Insite and in the one-year period after.   
• Drug use behaviours included rates of relapse into injection, drug use 
among former users, and the cessation of injection drug use among 
current users.   
• Also evaluated access to palliative and supportive care services, 
acceptability of drug use/relationship with staff, and whether or not 
environmental supports decreased drug related risks. 
 
VIDUS (871 
participants) 
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Kerr et al. (2007c) Insite, 
Vancouver 
• Evaluative observational study examining SIS’s impact on initiation and 
encouragement of injection drug use 
• Compared non-SIS using cohort’s # of initiations with SIS using cohort 
# of initiations 
SEOSI cohort * 
Wood et al. (2006b) 
 
Insite, 
Vancouver 
• Used data from the VPD on drug trafficking, assaults, robberies, vehicle 
break-ins, and thefts in the following areas: DTES, Victory Square, 
Chinatown, Gastown and Strathcona 
• Compared crime rates from the years before and after Insite opened 
VPD crime 
data for areas 
in site vicinity 
* 
Fitzgerald et al. 
(2010) 
MSIC, Sydney • Impact of the SIS opening on local crime (King Cross area) compared 
to the rest of the city 
• Longitudinal retrospective study over 11 year study period 
Computerized 
police reports * 
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7.5 Appendix E: Evaluation Matrix  
 
Evaluation Question #1: Are the services being provided as intended at the two SCS and adapting to client and community needs? 
 
Evaluation Sub-Questions Indicators Data Sources Data Collection Methods Timeframe Responsibility 
i. What is the pattern of client 
attendance at each SCS? 
  
# of client visits (total) SCS clients Access database or clinical notes 
(paper records) 
Ongoing  SCS staff 
# of unique clients (frequency of 
use) 
SCS clients Access database or clinical notes 
(paper records) 
Ongoing SCS staff 
Demographic of clients accessing 
SCS (age, gender, ethnicity) 
SCS clients Access database or clinical notes 
(paper records) 
Ongoing SCS staff 
Services accessed by clients SCS clients Access database or clinical notes 
(paper records) 
Ongoing SCS staff 
ii. Is each SCS providing wound 
care, vaccinations, and other 
health services onsite? 
  
# of clients receiving wound care, 
vaccination, and other health 
services 
 
SCS clients Access database or clinical notes Baseline, 6 
months, 1 
year 
SCS staff 
Evaluation Question #2: Are SCS services adapting to client and community needs? 
 
Evaluation Sub-Questions Indicators Data Sources Data Collection Methods Timeframe Responsibility 
i. Have there been any 
changes to the way SCS 
services are offered at 
each site?  
  
Changes to the way SCS services 
are offered 
 
Site Manager Key informant interviews  1 month, 6 
months 
Evaluator 
# of services offered (have services 
been added/removed?) 
Site Manager Key informant interviews  1 month, 6 
months 
Evaluator 
What are the similarities and 
differences between sites, Why? 
 
Site Manager Key informant interviews 1 month, 6 
months 
Evaluator 
ii. Are clients satisfied with the 
services offered at each SCS?  
  
% of clients that report being 
satisfied with services offered at 
SCS 
 
SCS clients 
 
 
 
 
Client satisfaction survey and/or 
comment cards 
1 month, 6 
months 
Evaluator, 
Lookout Staff 
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Satisfaction of clients in community  Clients in 
community 
(attend SCS at 
least once) 
PWUD in the community 
satisfaction survey  
1 month, 6 
months 
Evaluator, 
Lookout Staff 
iii. Are community members and 
key stakeholders supportive 
of each SCS?  
% of community members support 
SCS (within 500 m radius) 
 
Community 
members  
within 500 m 
radius of each 
site 
Online survey (link mailed out) 1 month pre, 
6 months 
post 
Fraser Health 
staff, Project 
Manager 
% of businesses/community 
organizations support SCS (within 
500 m radius) 
 
Business 
Persons within 
500 m radius 
of each site 
Online survey (link mailed out)  1 month pre, 
6 months 
post 
Fraser Health 
staff, Project 
Manager 
# of referrals from stakeholders to 
SCS  
 
SCS clients 
 
 
 
Client satisfaction/PWUD in the 
community survey 
 
1 month, 6 
months 
 
Evaluator, 
Lookout Staff 
 
Comment cards Ongoing 
 
Evaluator, SCS 
Staff 
 
Evaluation Question #3: Are the intended benefits of each SCS being recognized?  
 
Evaluation Sub-Questions Indicators Data Sources Data Collection Methods Timeframe Responsibility 
i.  Has there been a decrease in 
OD deaths among PWUD in 
the vicinity of the sites? 
  
# of OD deaths in vicinity before 
and after site opening (500m) 
PWUD in 
vicinity 
Coroner’s Records or 
Emergency Services 
(Ambulance, Fire, RCMP 
records) 
Pre, 
baseline, 
monthly 
Epidemiologist 
# of OD events successfully 
managed onsite  
 
SCS clients Access database, clinical notes Ongoing SCS staff 
ii. Has there been decreased 
emergency health care 
utilization among PWUD in 
the vicinity of the sites? 
# of emergency service calls and 
attendances  
 
EHS, fire, 
RCMP 
Access database and/or 
EHS, fire, RCMP records of 
attendances 
Pre, 
baseline, 
weekly 
Epidemiologist, 
Medical Health 
Officer  
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  # of ED presentations before and 
after SCS opening within vicinity 
(500 m radius) 
  
EHS data, fire, 
RCMP 
EHS, fire, RCMP records of 
transport to ED or 
 
SMH records of overdose ED 
presentations 
Pre, 
baseline, 
weekly 
 
 
 
Epidemiologist 
iii.  Has there been a reduction in 
HIV/HCV risk behaviour 
among clients? 
# of harm reduction supplies 
provided onsite 
 
SCS staff 
 
 
Access database 
 
6 months 
 
 
 
SCS Staff 
# of THN kits provided onsite 
 
BCCDC data BCCDC reporting 6 months, 
retrospective 
data 
collection 
Epidemiologist 
# clients receiving safe injection 
education  
SCS staff 
 
Access database, clinical notes 
 
Ongoing 
 
SCS staff 
 
 
SCS clients 
 
 
Client Satisfaction Survey  
PWUD in Community Survey 
 
1 month, 6 
months 
 
 
Evaluator, 
Lookout Staff 
# of clients report needle sharing SCS clients Client satisfaction survey  1 month, 6 
months 
 
 
Evaluator, 
Lookout Staff 
iv. Has there been increased 
interest/initiation of accessing 
OAT and other treatment 
services as a result of 
referrals from SCS sites? 
  
# of clients accessing OAT  
 
SCS clients OAT facilities data 
 
 
Baseline, 6 
months 
OAT facility 
staff 
 
Access database Baseline, 
6months 
SCS staff 
# of clients who are accessing OAT 
actually starting OAT 
SCS clients OAT facilities 
 
 
Baseline, 6 
months 
 
OAT facility 
staff 
 
Access database Baseline, 6 
months 
SCS staff 
# of clients referred to withdrawal 
management services, mental health 
services, MHSU services 
SCS clients Access databases 
 
 
Baseline, 6 
months 
SCS staff 
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# of clients accessing withdrawal 
management services, mental health 
services, and MHSU services 
SCS clients MHSU & Creekside databases  
 
Access database 
 
 
Baseline, 6 
months 
MHSU, 
Creekside, 
and/or SCS staff 
v. Has the amount of injection 
related litter in the area 
immediately surrounding the 
SCS decreased? 
 
# of improperly discarded syringes 
(and injection related litter)  
Surveillance 
data 
Public Injection/Injection 
Related litter tracking tool  
 
 
 
6 weeks pre, 
6 weeks post 
 
FH staff 
 
 
 
 
 
 
 
 
# of complaint calls related to 
injection litter pre/post 
 
Complaint 
calls to City 
Works Yard  
City Works Yard (tracking call-
outs/records)  
6 weeks pre, 
6 weeks post 
 
 
 
Evaluator 
Community 
and Business 
Persons within 
500 m radius 
of each site 
Online survey (link mailed out) 1 month pre, 
6 months 
post 
 
Project Manager 
vi. Has there been a reduction in 
public injection behaviour?  
# of people publically injecting  Surveillance 
data 
Public Injection/Injection 
Related litter tracking tool  
 
6 weeks pre, 
6 weeks post 
 
Mental Health 
Workers  
# of complaint calls related to public 
injection  
 
City of Surrey City of Surrey (may need to 
manually review cases) 
 
6 weeks pre, 
6 weeks post 
 
Evaluator 
Community 
and Business 
Persons within 
500 m radius 
of each site 
Online survey (link mailed out) 
 
1 month pre, 
6 months 
post 
Project Manager 
vii. Hast the amount of related 
crime remained the same in 
the vicinity of each SCS? 
 
# of crimes committed in vicinity  RCMP records RCMP Records Management 
System (RMS) data. ! Need to 
define vicinity and crimes to 
include (VPD included drug 
trafficking, assaults, robberies, 
theft and thefts from vehicle).   
12 months 
pre site 
opening/12 
months post 
Evaluator 
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7.6 Appendix F: Data Collection Tools 
 
7.6.1 Client Satisfaction Survey (1 month post) 
 
We would like to learn more about your thoughts on the Supervised Consumption Sites 
(SCS).  Your answers will help us understand how we can improve the services at the SCS.  
The survey should take 5-10 minutes to complete and you can stop the survey at any time.  
Thank you for your feedback! 
 
Handle:                                                                   
 
1. How often do you use the site to consume drugs? 
! More than once a day 
! Once a day 
! A few times a week 
! Once a week 
! A few times a month 
! Once a month 
! Less than once a month 
! Have not used the site in the past 
month (why?) 
                                               
 
2. How did you find out about the site? 
! Friend or acquaintance 
! Dealer 
! Poster 
! Media 
! Community organization 
! Outreach worker 
! Police 
! Other, please specify… 
                                                
 
3. How often in the last six months have you used a needle after someone else has already 
used it? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
 
4. How often in the last six months has someone else used a needle that you have already 
used? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
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5. Do any of the following features of the SCS affect how often you use at the site? 
a) Travel time to get to the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
b) Operating hours of SCS? 
! Always  
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
c) Waiting time to get into consumption room? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
d) The rules and regulations of the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
6. How would you rate the quality of services offered at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
 
7. How would you rate the facilities and equipment at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
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8. Do you think site staff are caring and accepting of people who use drugs? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
9. Have you ever received safer consumption advice or education at the site? 
! Yes  
! No 
 
10. Have you ever been referred from the SCS to another medical or social service? 
! Yes (Specify)                                             
! No 
 
11. What is your age? 
! 19 years or younger 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60 years or older 
 
 
12.   What gender do you identify as? 
! Female 
! Male 
! Transgender 
! Other, please specify… 
                                                    
 
 
13. Is there anything else you would like to tell us about your experience(s) at the site? 
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7.6.2 Client Satisfaction Survey (6 months post) 
 
We would like to learn more about your thoughts on the Supervised Consumption Sites 
(SCS).  Your answers will help us understand how we can improve the services at the SCS.  
The survey should take 5-10 minutes to complete and you can stop the survey at any time.  
Thank you for your feedback! 
 
Handle:                                                                   
 
 
1. How often do you use the site to consume drugs? 
! More than once a day 
! Once a day 
! A few times a week 
! Once a week 
! A few times a month 
! Once a month 
! Less than once a month 
! Only used it once 
! Have not used the site in the past six 
months (why?) 
                                                   
 
2. How did you find out about the site? 
! Friend or acquaintance 
! Dealer 
! Poster 
! Media 
! Community organization 
! Outreach worker 
! Police 
! Other, please specify… 
                                                
 
3. How often in the last six months have you used a needle after someone else has 
already used it? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
 
4. How often in the last six months has someone else used a needle that you have 
already used? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
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5. Do any of the following features of the SCS affect how often you use at the site? 
a) Travel time to get to the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
b) Operating hours of SCS? 
! Always  
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
c) Waiting time to get into consumption room? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
d) The rules and regulations of the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
6. How would you rate the quality of services offered at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
 
7. How would you rate the facilities and equipment at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
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8. Do you think site staff are caring and accepting of people who use drugs? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
9. Have you ever received safer consumption advice or education at the site? 
! Yes  
! No 
 
10. Have you ever been referred from the SCS to another medical or social service? 
! Yes (Specify) _________________ 
! No 
 
11. What is your age? 
! 19 years or younger 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60 years or older 
 
12. What gender do you identify as? 
! Female 
! Male 
! Transgender 
! Other, please specify… 
                                                     
 
13. Is there anything else you would like to tell us about your experience(s) at the site? 
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7.6.3  Persons Who Use Drugs in the Community Survey (1 month post) 
 
We would like to learn more about your thoughts on the Supervised Consumption Sites 
(SCS).  Your answers will help us understand how we can improve the services at the SCS.  
The survey should take 5-10 minutes to complete and you can stop the survey at any time.  
Thank you for your feedback! 
 
Handle (if 
applicable):                                                                   
 
1. Which site have you attended in the past? (Check all that apply) 
! 135a Portable SCS 
! Quibble Creek Sobering & Assessment Centre SCS 
! I have not gone to either SCS 
 
2. How often do you use the site to consume drugs? 
! More than once a day 
! Once a day 
! A few times a week 
! Once a week 
! A few times a month 
! Once a month 
! Less than once a month 
! Have not used the site in the past 
month (why?) 
                                               
 
3. Has anyone recommended the SCS to you? 
! Friend or acquaintance 
! Dealer 
! Poster 
! Media 
! Community organization 
! Outreach worker 
! Police 
! Other, please specify… 
                                                 
 
 
4. How often in the last six months have you used a needle after someone else has already 
used it? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
 
5. How often in the last six months has someone else used a needle that you have already 
used? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
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6. Do any of the following features of the SCS prevent you from going to a site?   
a) Travel time to get to the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
b) Operating hours of SCS? 
! Always  
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
c) Waiting time to get into the consumption room? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
d) The rules and regulations of the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
7. What do you think about the quality of services offered at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
 
8. What do you think about the facilities and equipment at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
 
 
 
 
  99 
 
9. Do you think site staff are caring and accepting of people who use drugs? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
10. If you have been to the site, have you ever received safer consumption advice or 
education at the site? 
! Yes  
! No 
! Not applicable 
 
11. If you have been to the site, have you ever been referred from the SCS to another 
medical or social service? 
! Yes (Specify)                                                     
! No 
! Not applicable 
 
12. What is your age? 
! 19 years or younger 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60 years or older 
 
13. What gender do you identify as? 
! Female 
! Male 
! Transgender 
! Other, please specify… 
                                                     
 
14. Is there anything else you would like to tell us about the site? 
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7.6.4  Persons Who Use Drugs in the Community Survey (6 months post) 
 
We would like to learn more about your thoughts on the Supervised Consumption Sites 
(SCS).  Your answers will help us understand how we can improve the services at the SCS.  
The survey should take 5-10 minutes to complete and you can stop the survey at any time.  
Thank you for your feedback! 
 
Handle (if 
applicable):                                                                   
 
1. Which site have you attended in the past? (Check all that apply) 
! 135a Portable SCS 
! Quibble Creek Sobering & Assessment Centre SCS 
! I have not gone to either SCS 
 
2. How often did you use the site to consume drugs? 
! More than once a day 
! Once a day 
! A few times a week 
! Once a week 
! A few times a month 
! Once a month 
! Less than once a month 
! Only used it once 
! Never (why?) 
                                                   
 
3. Has anyone recommended the SCS to you? 
! Friend or acquaintance 
! Dealer 
! Poster 
! Media 
! Community organization 
! Outreach worker 
! Police 
! Other, please specify… 
                                                
 
4. How often in the last six months have you used a needle after someone else has already 
used it? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
 
5. How often in the last six months has someone else used a needle that you have already 
used? 
! Always (100% of the time) 
! Usually (over 75% of the time) 
! Sometimes (26% to 74% of the time) 
! Occasionally (Under 25% of the time) 
! Never (0% of the time) 
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6. Do any of the following features of the SCS prevent you from going to a site?   
a) Travel time to get to the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
b) Operating hours of SCS? 
! Always  
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
c) Waiting time to get into the consumption room? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
d) The rules and regulations of the site? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
7. What do you think about the quality of services offered at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
 
8. What do you think about the facilities and equipment at the site? 
! Excellent 
! Good 
! Fair 
! Poor 
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9. Do you think site staff are caring and accepting of people who use drugs? 
! Always 
! Usually 
! Sometimes 
! Occasionally 
! Never 
 
10. If you have been to the site, have you ever received safer consumption advice or 
education at the site? 
! Yes  
! No 
! Not applicable 
 
11. If you have been to the site, have you ever been referred from the SCS to another 
medical or social service? 
! Yes (Specify)                                                     
! No 
! Not applicable 
12. What is your age? 
! 19 years or younger 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60 years or older 
 
13. What gender do you identify as? 
! Female 
! Male 
! Transgender 
! Other, please specify… 
                                                     
 
14. Is there anything else you would like to tell us about the site? 
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7.6.5  Community and Business Persons Survey (1 month pre) 
 
We would like to learn more about the impact of the Supervised Consumption Site (SCS) being implemented near your 
home or business.  We are asking all residents or business persons within a 500 metre radius of an SCS to complete 
this survey.  Your answers will help us understand community concerns and/or satisfaction with the site. The survey 
should only take 5 minutes and you can stop the survey at any time.  Thank you for your feedback! 
 
  
 
1. Based on the maps above, which SCS is closest to your business or residence?
! 135a Portable SCS 
! Quibble Creek Sobering & Assessment Centre SCS 
 
2. Are you a business person or resident in the area? 
! Business person 
! Resident 
 
3. How long have you resided or operated a business in the area? 
! Less than 1 year 
! 1-2 years 
! 3-4 years 
! 5 or more years 
 
4. What is your age? 
! Under 19 years old 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60-69 years old 
! 70-79 years old 
! 80 years or older
 
 
 
135A SCS   Quibble Creek  
SCS 
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5. How supportive are you of an SCS being implemented? 
! Very unsupportive 
! Unsupportive 
! Neither supportive or unsupportive 
! Supportive 
! Very supportive 
 
6. What kind of impact do you expect the SCS will have? 
! Very negative impact 
! Somewhat negative impact 
! No impact 
! Somewhat positive impact 
! Very positive impact 
 
7. When did you last see someone using injection drugs in a public place in the area 
shown on the map?
! Within the last day 
! Within the last week 
! Within the last month 
! Within the last six months 
! Within the last year 
! Never 
 
8. When did you last see a discarded syringe in the area shown on the map? 
! Within the last day 
! Within the last week 
! Within the last month 
! Within the last six months 
! Within the last year 
! Never
 
9. Based on research, the following are some anticipated benefits of implementing SCS 
sites.  What do you think is the likelihood of each of these benefits occurring in the 
vicinity of the SCS you are closest to? 
 
a. Fewer fatal drug overdoses 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
b. Reductions in emergency health care usages (cost savings) 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
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c. Decreased number of drug users with HIV/HCV  
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
d. Increased number of drug users accessing treatment 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
e. Less injection related litter in the neighbourhood 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
f. Less public injection in the neighbourhood 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
g. Are there any other advantages to implementing an SCS you can think of? Please 
specify…                                      
 
10. Based on research, the following are some common concerns with implementing SCS 
sites.  What do you think is the likelihood of each of these concerns occurring in the 
vicinity of the SCS you are closest to? 
 
a. Drug users may be attracted to the area 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
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b. Drug dealers may be attracted to the area 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
c. Drug use may be encouraged in the area 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
d. Crime may increase in the area 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
e. Public injecting or discarded syringes may be more common 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
f. The SCS may not address the drug problem 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
 
g. I have no concerns about the SCS 
! Extremely likely 
! Likely 
! Neutral 
! Unlikely 
! Extremely unlikely 
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h. Are there any other concerns with implementing an SCS you can think of? Please 
specify…                                       
 
 
11. Would you like to share any other thoughts with us about the SCS being implemented in 
your neighbourhood? 
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7.6.6  Community and Business Persons Survey (6 months post) 
 
We would like to learn more about the impact of the Supervised Consumption Site (SCS) being implemented near your 
home or business.  We are asking all residents or business persons within a 500 metre radius of an SCS to complete 
this survey.  Your answers will help us understand community concerns and/or satisfaction with the site. The survey 
should only take 5 minutes and you can stop the survey at any time.  Thank you for your feedback! 
 
  
 
1. Based on the maps above, which SCS is closest to your business or residence?
! 135a Portable SCS 
! Quibble Creek Sobering & Assessment Centre SCS 
 
2. Are you a business person or resident in the area? 
! Business person 
! Resident 
 
3. How long have you resided or operated a business in the area? 
! Less than 1 year 
! 1-2 years 
! 3-4 years 
! 5 or more years 
 
4. What is your age? 
! Under 19 years old 
! 20-29 years old 
! 30-39 years old 
! 40-49 years old 
! 50-59 years old 
! 60-69 years old 
! 70-79 years old 
! 80 years or older
 
5. How supportive are you of the SCS in your area? 
! Very unsupportive 
135A SCS   Quibble Creek  
SCS 
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! Unsupportive 
! Neither supportive or unsupportive 
! Supportive 
! Very supportive 
 
6. What kind of impact do you think the SCS has had? 
! Very negative impact 
! Somewhat negative impact 
! No impact 
! Somewhat positive impact 
! Very positive impact 
 
7. When did you last see someone using injection drugs in a public place in the area 
shown on the map?
! Within the last day 
! Within the last week 
! Within the last month 
! Within the last six months 
! Within the last year 
! Never 
 
8. When did you last see a discarded syringe in the area shown on the map? 
! Within the last day 
! Within the last week 
! Within the last month 
! Within the last six months 
! Within the last year 
! Never
 
9. Based on research, the following are some anticipated benefits of implementing SCS 
sites.  Do you think that any of these benefits have occurred as a result of the services 
provided at the SCS you are closest to? 
 
a. Fewer fatal drug overdoses 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
b. Reductions in emergency health care usages (cost savings) 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
c. Decreased number of drug users with HIV/HCV  
! Strongly agree 
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! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
d. Increased number of drug users accessing treatment 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
e. Less injection related litter in the neighbourhood 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
f. Less public injection in the neighbourhood 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
g. Are there any other advantages to implementing an SCS you can think of? Please 
specify…                                       
 
 
10. Based on research, the following are some common concerns with SCS sites.  Do you 
think that any of these concerns have occurred as a result of the services provided at 
the SCS you are closest to? 
 
a. Drug users are attracted to the area 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
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b. Drug dealers are attracted to the area 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
c. Drug use is encouraged in the area 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
d. Crime has increased in the area 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
e. Public injecting or discarded syringes are more common 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
f. The SCS does not address the drug problem 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
 
g. I have no concerns about the SCS 
! Strongly agree 
! Agree 
! Neither agree or disagree 
! Disagree 
! Strongly disagree 
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h. Are there any other concerns with implementing an SCS you can think of? Please 
specify…                                       
 
11. Would you like to share any other thoughts with us about the SCS being implemented in 
your neighbourhood? 
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7.6.7  Key Informant Interview Guide 
 
Participants:  Site Manager(s) 
Administered: 1 month, 6 months 
Interview Preamble:  Thank you for agreeing to assist us with the evaluation of the SCS.  
As a reminder, this interview is being conducted to help us find out more about how the 
SCS services are being offered and any changes that have occurred since the SCS 
opened.     This discussion should last no longer than 20 minutes.  I also want to remind 
you that you can always skip answering a question and you can end the interview at any 
time.   I may be taking notes throughout the interview to summarize your feedback.  If 
you are ready, we will get started… 
 
Interview Guide: 
 
1. From your perspective, are the sites operating as intended? Why or why not? 
" Are the sites achieving their intended outcomes?  
" Intended outcomes= clients satisfied, community supportive, OD deaths reduced, 
HIV/HCV risk behaviour reduced, reduced emergency health care usage, 
increased referrals/access to treatment, decreased public injection/injection related 
litter, and no increases in crime.   
 
2. What are some of the main strengths with how the sites operate? 
" What are the main strengths specific to 135A? QC SAC? 
 
3. What are some of the main challenges with how the sites operate? 
" For instance, are there any challenges with location, co-location with ____ 
(RCMP trailer, SMH, etc.), staff, staffing profile, community members, etc. 
" What are the main challenges specific to QC SAC? 135a? 
 
4. Since the site opened, have there been any changes to the way existing services are 
offered?  Could you please describe these changes? 
" Why was                     service changed? 
" In your opinion, has the change made the service better or worse?  
" Are there any services that you think should be changed? Why? 
 
5. Since the site opened, have there been any services that have been added or removed?  
Could you please describe these services? 
" Why was                     service added or removed? 
" In your opinion, has the addition/removal of this service(s) resulted in better 
outcomes at the SCS?  
" Are there any other services that you would like to see added or removed? Why? 
 
6. Is there anything else you think I should know? 
 
This concludes our discussion.  I would like to thank you for taking the time to assist us 
with the evaluation of the SCS.   
 114 
 
7.6.8  Public Injection/Injection Related Litter Study Zone Map for 135a SCS  
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7.6.10  Public Injection/Injection Related Litter Tracking Tools 
 
PUBLIC INJECTION TRACKING 
 
 
 
 
 
 
 
 
 
 
 
 
 
INJECTION RELATED LITTER TRACKING 
 
 
 
 
 
 
 
 
Date (M/D/Y): Completed by: 
Time (provide range of time, i.e. 9am-12pm):  Site (135a or QC SAC Zone): 
Date # Public 
Injection 
Events 
# of people 
injecting 
Zone Description 
     
     
     
Date (M/D/Y): Completed by: 
Time (provide range of time, i.e. 9am-12pm):  Site (135a or QC SAC Zone): 
Date # of discarded 
syringes 
# injection 
related litter 
Zone Description 
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7.6.11   Comment Cards 
 
WE	WOULD	LIKE	TO	HEAR	FROM	YOU!	
	
For	each	question	below,	circle	the	number		
to	the	right	that	best	fits	or	provide	a	written	response	
 
Feedback	Question	
Scale	
Poor	 Good	 Excellent	
How	would	you	rate	the	services	offered	here?	 1	 2	 3	 4	 5	
How	would	you	rate	the	friendliness	of	our	staff?	 1	 2	 3	 4	 5	
What	do	you	think	about	the	location	of	this	site?		 1	 2	 3	 4	 5	
What	do	you	think	of	the	hours	we	are	open?	 1	 2	 3	 4	 5	
How	would	you	rate	your	safety	and	security	at	the	
site?	 1	 2	 3	 4	 5	
	
How	many	times	have	you	attended	this	site	in	the	
past	year?	 1	time	 2	times	 3	times	 4	times	 5+	times	
How	did	you	hear	about	us?	 	
Is	there	anything	else	you	would	like	to	tell	us	about	
your	experiences	at	the	site?	(Please	feel	free	to	
write	on	the	back	of	the	card	if	you	need	more	room)	
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7.7 Appendix G: Critical Reflection 
 
 This capstone project was a very rewarding experience for me as I approach the 
end of my MPH program.   During this project, I was able to apply a range of knowledge 
and skills I have learned throughout the MPH while producing a tool for a large health 
care organization.  I was especially grateful to have had the opportunity to work at Fraser 
Health while completing my project.  My proximity to people involved in the SCS 
implementation/evaluation allowed for greater collaboration with the organization.   As I 
am hoping to work in the field of program planning and evaluation upon graduating from 
the MPH, I was thrilled to have had the opportunity to enhance my evaluation skills while 
completing this project.  Planning the evaluation closely with the FH Evaluation 
Specialist, Rachel Douglas, allowed me to learn various practical evaluation strategies.  
Working with my supervisor, Dr. Small, also allowed me to expand my knowledge of 
research methodologies, people who use drugs, and harm reduction approaches.  Finally, 
as the primary person developing the evaluation plan, I conducted a rigorous literature 
review and created an evidence summary, logic model, evaluation matrix, and several 
data collection strategies.  By completing this comprehensive evaluation plan, I have 
certainly developed expertise in the area of program evaluation.   
 I am pleased that this project will be used by FH to guide their evaluation and 
could help positively impact population health in the Fraser Region.  By developing the 
evaluation plan with FH directly, I am certain that the product aligns closely with their 
evaluation needs and will allow for greater understanding of the effectiveness of SCS 
programs.  Ultimately, my hope is that FH will use the results of this evaluation to 
improve the services and conditions for PWUD.  Finally, I expect that this evaluation 
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plan will be useful for other health care organizations who might be implementing SCS 
sites in their communities.  For instance, other health authorities have contacted FH for 
advice for their own evaluation plans and have used pieces from my plan to guide their 
own.   
 Although I was very satisfied with my capstone experience, I wish I had 
additional time at the outset to learn more about PWUD in FH communities.  I believe 
the evaluation plan could have been stronger with more input from people who access the 
sites.  However, I am hopeful that by including several opportunities for feedback from 
clients and PWUD within the evaluation, that FH will be able to continue refining the 
evaluation and their services to meet the needs of these stakeholders.    
 Having the chance to work on this timely and worthwhile initiative with FH 
exceeded my expectations for a capstone project.  I am looking forward to applying this 
learning and experience in my future work as a public health practitioner. 
